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Lymphoid tyrosine phosphatase (LYP) is an intriguing therapeutic target for the 
treatment of several autoimmune disorders including anaphylaxis. Despite this, its precise 
biological functions in signaling cascades and cellular physiology are still poorly 
understood. Chemical probes can be beneficial for addressing biological questions 
pertaining to LYP by creating chemical knockdowns as well as for therapeutic inhibition 
of LYP. However, to be useful, these chemical probes need to be selective for LYP. 
Crucial insights about selective targeting of LYP can be gained from studying how LYP 
demonstrates substrate specificity in vivo. The substrate specificity of LYP in vivo can be 
attributed to the interactions of the substrates with the nonconserved features of LYP and 
to the biological regulation of LYP. Exploiting these interactions with nonconserved 
features of the LYP catalytic domain as well as mimicking the regulatory mechanisms 
can help in targeting LYP selectively over other homologous protein tyrosine 
phosphatases (PTPs). Peptides, being the closest mimics of biological substrates of LYP, 
can target both the conserved and nonconserved features of LYP. We have taken 
advantage of these desirable features of peptides by using a peptide substrate in screening 
for potent and selective LYP inhibitors. When used in inhibitor screens, the inhibitor 
potencies against this peptide substrate were found to correlate more strongly with the 
biological activity than those against a traditional small molecule substrate. From this 
  iv 
inhibitor screening exercise, we identified epigallocatechin-3,5-digallate as the most 
potent LYP inhibitor reported so far (IC50 = 50 nM). We have also exploited one of the 
regulatory mechanisms of LYP, oxidation of the catalytic cysteine residue, to identify 
thiuram disulfides as a new class of covalent inhibitors of LYP. The best hit from a 
library of thiuram disulfides screened, compound 13, was shown to inhibit LYP with Ki 
of 1.1 ± 0.4 µM and kinact of 0.0040 ± 0.0007 s-1 in a pseudo-irreversible manner by 
forming mixed disulfide with the LYP. We have also developed peptide-based covalent 
inhibitors of LYP that take advantage of the selectivity offered by the peptide sequences 
and combine it with the utility of an electrophilic, cysteine-reactive, phosphotyrosine 
(pY) mimetic, warhead. We have separately optimized the electrophilic warhead and the 
peptide sequence to identify LDLL-(VsN)-SDDD as the best peptide-based covalent LYP 
inhibitor. This optimized inhibitor inhibited LYP with an IC50 of 20 µM and showed 
selective inhibition of LYP over other homologous PTPs. In summary, we have 
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1.1 Protein tyrosine phosphatases 
1.1.1 Phosphotyrosine-dependent cellular signaling 
Protein phosphorylation is the most common posttranslational modification, 
playing a key role in signal transduction (1). Besides its role in signal transduction, 
protein phosphorylation can also determine the rate of protein degradation, the ability of 
proteins to translocate from one subcellular compartment to another, and the interaction 
of a protein with other proteins and bivalent cations. It has been estimated that 30% of all 
cellular proteins are phosphorylated on at least one residue (2, 3). Analysis of acid-stable 
phospho-amino acids reveals that of the residues that are phosphorylated in cellular 
proteins, 90% are serine (S), 10% are threonine (T) and 0.05% are tyrosine (Y) (4). There 
are two broad classes of enzymes that regulate the levels of protein phosphorylation in 
cells. Protein kinases catalyze the transfer of the γ-phosphate from adenosine triphosphate 
(ATP) to a specific residue on a protein. Protein phosphatases dephosphorylate the 
phosphorylated amino acid residue. Abnormalities in levels of protein phosphorylation 
play a role in pathogenesis of human diseases and many naturally occurring toxins exert 
their effects by altering the phosphorylation of proteins. For example, a virulence factor 
for Yersinia pestis, the bacteria that causes bubonic plague, is a protein tyrosine 
phosphatase (PTP) called YopH, which causes uncontrolled dephosphorylation of many 
phosphotyrosine (pY) residues helping the bacteria evade host defense mechanisms 
resulting in fatality (5, 6). 
Although tyrosine phosphorylation is rare compared to serine and threonine 
phosphorylation, it plays numerous important roles in eukaryotic physiology. Tyrosine 






related to proliferation and differentiation, shape, motility, metabolism, migration and 
survival of the cell, communication between and within cells and cellular processes like 
regulation of gene transcription, mRNA processing and transport of molecules in or out 
cells (7, 8). Abnormal levels of tyrosine phosphorylation result in several human diseases 
including cancers, diabetes, hypertension and autoimmune disorders such as rheumatoid 
arthritis (9). Therefore, restoring the normal levels of tyrosine phosphorylation is crucial 
for treatment of these disorders.  
Tyrosine phosphorylation levels in the cells are regulated by the balancing actions 
of two classes of enzymes, protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). However, until the late 1990s, PTKs were thought to be the main 
regulators of the tyrosine phosphorylation in cells while PTPs were considered primarily 
housekeeping enzymes because development of our knowledge about actions, targets, 
regulation and roles in normal human physiology and human diseases of PTKs had 
outpaced that of PTPs (10). This can be partially attributed to the fact that PTPs were 
discovered about a decade later than the PTKs. Therefore, until recently, barring protein 
tyrosine phosphatase 1B (PTP1B), the majority of drug discovery efforts were focused on 
developing compounds targeting PTKs. However, it is now clear that PTPs are actually 
highly specific and tightly regulated enzymes that play crucial roles in several biological 
processes (11).  
The human genome contains a total of 107 genes that encode for the amino acid 
sequence (H/V)C(X)5R(S/T), also called the PTP signature motif, in the catalytic domain 
(12). Eighty one out of these 107 genes are predicted to encode a catalytically active PTP 






genes encoding for PTKs resulting in 85 catalytically active PTKs (13). The 
approximately equal numbers of active PTPs and PTKs in humans, coupled with recent 
experimental evidence that both the PTPs and PTKs have similar specificities for their 
substrates, both are tightly regulated and are critical in cellular signaling, indicate that 
both PTKs and PTPs are interesting therapeutic targets (14). 
Although the developments over the last decade or so have helped us understand 
PTPs a little better, there is still a dearth in knowledge about pathological and 
physiological roles of individual PTPs and the mechanisms of regulations of PTPs (15). 
The major barrier towards developing this understanding is a lack of tools suitable for 
studying activities and regulations of the PTPs in vivo. Complimentary use of genomic 
and chemical approaches can help in improving our understanding of this class of 
enzymes.  
 
1.1.2 The protein tyrosine phosphatase enzyme family 
Unlike kinases where PTKs share sequence identity with serine/threonine kinases, 
PTPs do not show sequence similarity with serine/threonine phosphatases or alkaline 
phosphatases (16). The PTP superfamily of enzymes is defined by the amino acid 
sequence (H/V)C(X)5R(S/T), also called the PTP signature motif, in the catalytic domain 
(17). This signature motif includes the catalytic cysteine residue and an arginine residue 
that play a key role in recognizing the pY moiety of the substrate. The presence of a 
conserved histidine residue and the α-helix following the phosphate binding loop (P-
loop) in PTPs generates a dipole that contributes to the extremely low pKa (4.5-5.5) of the 






physiological pH (18). Owing to the highly conserved active site, all PTPs use a common 
catalytic mechanism for hydrolysis of their phosphorylated substrate as shown in Figure 
1.1 (19, 20). Upon binding of the pY substrate to the active site of the PTPs, the 
phosphate undergoes nucleophilic attack from the catalytic cysteine residue. The 
phosphate group is cleaved off of the substrate and is transferred to the catalytic cysteine 
residue to form a phospho-cysteinyl intermediate (21, 22). A conserved aspartic acid 
residue then acts as a general acid, transferring a proton to the leaving group (tyrosine-
containing substrate) and facilitating the expulsion of the product (23). The same aspartic 
acid residue then acts as a general base by abstracting a proton from a water molecule, 
which in turn nucleophilically attacks and hydrolyzes the phospho-cysteinyl intermediate 


















Owing to the conserved active site, the catalytic domains of all the PTPs show 
high similarity. All 107 PTPs contain at least one ~280 amino acid residue PTP catalytic 
domain. Based on the amino acid sequences in this catalytic domain, PTPs can be 
classified into four families (Figure 1.2) (12). Another key structural feature of PTPs is 
their multiple modular domains. These additional domains may include SH2 domains, 
extracellular fibronectin type (FN) and immunoglobulin repeats. The additional non-
catalytic domains of PTPs help in their regulation, interaction with other proteins, and 
subcellular localization. The arrangement and homology between these additional non-
catalytic domains help in further subclassification of PTPs.  
Class I cysteine-based PTPs constitute the largest family of PTPs with a total of 
99 members. This class of PTPs can be broadly divided based on their substrate 
preferences into two subclasses comprising of 38 classical PTPs and 61 “dual-specific” 
protein phosphatases (DSPs). Each of these subclasses can be further divided into several 
subfamilies based on arrangement and homology between the domains. The 38 classical 
PTPs contain homologous PTP domains that strictly dephosphorylate only the pY 
residues. Classical PTPs contain a tyrosine residue in the pY recognition loop present 
adjacent to the P-loop, which forms one side of the phosphate binding cleft to determine 
the depth of the active site (typically ~ 9Å) (11). This in turn renders classical PTPs 
selective for pY over phosphoserine (pS) and phosphothreonine (pT) as the phosphate 
group of only pY can be accessible to the catalytic cysteine residue located at the bottom 
of the P-loop. Classical PTPs can be further divided into 21 receptor-like PTPs (RPTPs) 
and 17 intracellular nonreceptor PTPs (NRPTPs) (24). Members of the individual 
























Figure 1.2. Classification and domain structures of all 107 genetically encoded PTPs. 









For example, PTP1B and T-cell protein tyrosine phosphatase (TCPTP), the 
members of NT1 subfamily of classical PTPs, show 74% sequence identity in the 
catalytic domain while the members of NT4 subfamily of classical PTPs, lymphoid 
tyrosine phosphatase (LYP) and PTP-PEST, show 70% sequence identity in the catalytic 
domain (25, 26).  
The 61 DSPs are much less conserved and can be subdivided into several 
subfamilies. The subfamily of DSPs that specifically dephosphorylate proteins from the 
mitogen-activated protein (MAP) kinase family, namely Erk, Jnk and p38, contain 11 
PTPs (27, 28). These MAP kinase phosphatases (MKPs) contain a MAP kinase targeting 
motif and show dual specificity for pY and phosphothreonine (pT) residues. The 
subfamily of atypical DSPs consists of 19 poorly characterized PTPs that contain fewer 
than 250 amino acid residues each and lack specific MAP kinase targeting motif (27). 
Members of the PRL subfamily are found in regenerative liver while slingshot 
phosphatases are thought to dephosphorylate proteins involved in actin reorganization 
(29, 30). CDC14 subfamily is involved in dephosphorylation of pT of the Cdk-activation 
loop and inactivation of cyclin-dependent kinases (31). Members of the PTEN subfamily 
of PTPs dephosphorylate phosphatidylinositol-3,4,5-triphosphate at the plasma 
membrane while the members of the myotubularins dephosphorylate 
phosphatidylinositol-3-phosphate on internal cell membranes (32).  
The class II cysteine-based PTPs family is represented in the human genome by a 
single gene encoding for an 18 kDa low molecular weight PTP (LMPTP). Human 
LMPTP can dephosphorylate a number of tyrosine kinases and their substrates but the 






PTPs consists of 3 cell cycle regulators that dephosphorylate cyclin dependent kinases 
(Cdks) at their dually phosphorylated N-terminal threonine-tyrosine motif (33). 
Dephosphorylation of pY and pT of Cdks by the class III PTPs in turn drives progression 
of cells through the cell cycle. The class IV aspartate-based PTPs use a nucleophilic 
aspartate residue for the dephosphorylation of pY and possibly phosphoserine (pS) 
residue (34). However, a clear, structurally based definition of this subfamily of PTPs is 
not available.  
 
1.2 Chemical probes for protein tyrosine phosphatases 
1.2.1 Need for chemical probes for protein tyrosine phosphatases 
Despite sharing a conserved active site and a common mechanism for substrate 
dephosphorylation, PTPs have distinct physiological functions in vivo. Establishing the 
crucial roles of PTPs has led to the identification of several therapeutic targets. For 
example, PTP1B is a key negative regulator of insulin receptor and leptin receptor-
mediated signaling pathways and plays important roles in regulating body weight, 
glucose homeostasis and energy expenditure (35, 36). Therefore, PTP1B is an interesting 
therapeutic target for treatment of diabetes and obesity. Another well-studied PTP, Src 
homology-2 domain-enriched tyrosine phosphatase (SHP2) is associated with 
development of Noonan syndrome and acute myeloid leukemia, and therefore it is an 
important target for anticancer therapeutics (37). Despite some improvements in our 
knowledge of the mechanisms and functions of PTPs in last two decades, there are still 
gaps in our understanding of how they drive particular biological processes. PTP 






transduction. For example, CD45 catalyzed dephosphorylation of its substrate turns on 
TCR signaling while LYP catalyzed dephosphorylation of its substrates turns off TCR 
signaling (38). Therefore a detailed understanding of how malfunction of a particular 
PTP causes a human disease is extremely critical. Also, isolating and establishing 
activities of individual PTPs is essential for PTP target identification and validation. 
Our current appreciation of the PTPs has been developed primarily through the 
use of genomic techniques such as gene knockout and protein overexpression. However, 
these genomic approaches have several limitations (37). Overexpression of a protein in 
cells enhances its effects on its targets, which helps in their identification. However, at 
high expression levels, proteins can show several nonspecific effects that would not be 
observed at physiological or pathological concentrations. Gene knockout is a powerful 
technique because of its specificity for the target of interest but it is quite tedious and can 
lead to lethality. In addition, the loss of activity of one PTP can sometimes be 
compensated for through other mechanisms during embryonic development, making it 
difficult to attribute all of the biological effects of the knockout solely to loss of PTP 
activity. RNA interference (RNAi) typically uses a small interfering RNA (siRNA) that 
causes ablation of expression of the target protein by destroying mRNA encoding for it. 
However, RNAs are highly polar and charged and therefore, sufficient cellular delivery is 
challenging. Besides, RNAi can cause general translational attenuation as well as non-
specific destruction of mRNAs leading to the off-target effects (39). Measurement of 
enzyme abundance by determining mRNA levels suffers from the disadvantage that it 
does not reflect the activities of the PTPs. PTP activity is highly regulated through 






of the protein often does not correlate with the activity (11). The limitations of genomic 
approaches warrant the complimentary use of chemical approaches for studying PTPs 
(37). Chemical probes are effective in profiling the functional states of various enzymes 
in complex environments by providing temporal control of their activities, which in turn 
can lead to target identification and the discovery of previously uncharacterized enzyme 
activity by creating chemical knockdowns of the proteins of interest (40-42). In addition, 
the chemical probes used for the chemical knockdown can provide a direct validation of 
novel therapeutic targets and offer insights that can help in subsequent development of 
new therapeutic agents. 
 
1.2.2 Challenges for chemical probes for protein tyrosine phosphatases 
There are two major challenges in development of chemical probes for PTPs, 
namely, selectivity and bioavailability (43). Both of these challenges arise from features 
inherent in the active site of the PTPs. As described earlier, all PTPs share a conserved 
active site and a common catalytic mechanism for substrate dephosphorylation. 
Therefore, achieving selectivity for one PTP over the others by using inhibitors binding 
only to the active site of PTPs is extremely challenging. In addition, the conserved active 
site of PTPs is highly positively charged. Therefore it is no surprise that most of the 
inhibitors targeting the PTP active site are negatively charged and suffer from low cell 
permeability and bioavailability. However, similar challenges have been resolved in the 
design of therapeutically relevant PTK inhibitors, and it is likely that the right approaches 






lies in carefully designing chemical probes, taking hints from how PTPs achieve their 
remarkable substrate selectivity in vivo. 
 
1.3 The lymphoid tyrosine phosphatase: an intriguing therapeutic target 
1.3.1 The lymphoid tyrosine phosphatase in autoimmunity 
Recently, LYP has been recognized as an intriguing therapeutic target because of 
its association with human autoimmunity (44-48). LYP is a classical NRPTP belonging 
to the NT4 subfamily. Encoded by PTPN22 gene, LYP is expressed exclusively in 
hematopoietic cells (44, 49). It is a 105 kDa protein that contains two distinct domains; 
an approximately 300 amino acid N-terminal PTP domain and an approximately 200 
amino acid C-terminal domain that contains four proline-rich motifs. The N-terminal 
catalytic domain and the C-terminal domain are separated by approximately 300 amino 
acids, frequently called the ‘interdomain’ (50). LYP is a potent negative regulator of T-
cell receptor (TCR) signaling (51). When an antigenic peptide bound to the major 
histocompatibility complex (MHC) class II molecule binds to the TCR and the coreceptor 
CD4, it initiates a signaling cascade (Figure 1.3). LYP elicits its potent inhibitory effect 
on TCR signaling by dephosphorylating several key proteins in this signaling cascade 
including the Src family kinases lymphocyte-specific protein tyrosine kinase (Lck) and 
Fyn, zeta-chain-associated protein kinase 70 (ZAP-70) and TCRzeta (52). A single 
nucleotide polymorphism (SNP), C1858T, in the PTPN22 gene results in a variant of 
LYP carrying W620 instead of R620 in the C-terminal domain (53). This LYP-W620 is a 
gain of function variant of LYP that shows increased phosphatase activity and therefore 
















Figure 1.3. Proposed model for negative regulatory role of LYP in TCR signaling (55). 
Reprinted by permission from Macmillan Publishers Ltd, Nat. Chem. Biol. 8, 437-446, 
2012. 
 
autoimmunity causing disease predisposition through a variety of mechanisms including 
altered thymic selection, reduced T-helper activity and decreased function of regulatory 
T-cells (56). LYP-W620 has been found to predispose humans to a range of autoimmune 
disorders including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, 
myasthenia gravis, Graves’ and Addison’s disease and others (57). Correspondingly, the 
G788A SNP in the PTPN22 gene leads to a LYP variant containing Q263 instead of 
R263 in the catalytic domain (58). This LYP-Q263 is a loss of function variant with 
reduced phosphatase activity and it is found to be protective against systemic lupus 






immune response and potential for development of LYP inhibitors for treatment of 
autoimmune disorders.  
 
1.3.2 Chemical probes for lymphoid tyrosine phosphatase: need and utility 
While inhibition of LYP activity could be therapeutically beneficial, nonspecific 
inhibition of other T-cell derived PTPs is likely to be detrimental. For example, the 
ubiquitously expressed PTP-PEST is an enzyme that shares 70% sequence identity with 
LYP in the catalytic domain (26). PTP-PEST is essential in development, and cannot be 
removed without embryotoxicity in mice (59). Another PTP, CD45, catalyzes 
dephosphorylation of its substrate (Lck pY505) that turns on TCR signaling (38). 
Therefore, inhibition of CD45 activity would counteract any benefit obtained from 
inhibition of LYP. In addition to LYP, PTP-PEST and CD45, about 50 PTPs including 
HePTP, TCPTP, SHP1, SHP2, PTPH1, PTP36, PTP-MEG1, LMPTP, PTEN are 
expressed in T cells (60). These PTPs, just like LYP, play specific roles in T cells and 
therefore, nonselective inhibition of LYP can lead unwanted side effects. Therefore if 
therapeutic LYP inhibitors are to be developed, the issue of PTP selectivity must be 
addressed.  
Considerable effort has been devoted to the development of potent, selective 
inhibitors of LYP and other PTPs for use as chemical probes and potential therapeutic 
leads, but there are still several challenges in the field (16, 37, 61-64). Our efforts of 
screening compound libraries in the quest for identifying potent and selective LYP 
inhibitors has lead us to the gold(I)-based drugs, aurothioglucose and auranofin, as potent 






C28 (Figure 1.4A) as the most selective LYP inhibitor reported so far (45, 66). The 
papers describing this work are published in J. Med. Chem. and J. Inorg. Biochem. 
Recently, our collaborators have used C28 to create a chemical knockdown of LYP in 
mast cells and this work is published in Allergy (67). The chemical knockdown 
accurately mimicked effects of gene knockout and was instrumental in establishing the 
positive regulatory role of LYP in mast cell degranulation and anaphylaxis. Furthermore, 
chemical knockdown of the mouse ortholog of LYP, PEST-domain enriched tyrosine 
phosphatase (PEP), has been shown to alleviate anaphylaxis in mice (Figure 1.4B). It was 
also shown that inhibition of PEP is synergistic with dexamethasone in the treatment of 
anaphylaxis. This study underlines the importance of chemical knockdowns in studying 
the physiological and pathological roles of PTPs. 
Despite this significant finding, very little information is available about the 
substrates, abundance, localization and regulation of LYP in mast cells. Also, details of 
regulation of LYP in TCR signaling are still missing especially those pertaining to the 
abundance and subcellular localization of active versus inactive LYP in presence and 
absence of TCR stimulation. Although C28 has been instrumental in establishing the role 
of LYP in anaphylaxis, it cannot help in addressing other problems pertinent to LYP. 
Other potent and selective inhibitors, which can be covalently attached to LYP, can help 
in addressing these issues. For developing potent and selective inhibitors, key insights 


















Fig. 1.4. Utility of a LYP inhibitor in the treatment of anaphylaxis. (A) C28, the best 
LYP inhibitor from the library of gold (I) phosphines, (B) change in body temperature of 
mice induced with anaphylaxis upon treatment with PBS (control, black), dexamethasone 






















1.4 Substrate selectivity in lymphoid tyrosine phosphatase 
Like several other PTPs, LYP exhibits high substrate specificity in vivo, which 
can be attributed both to the nonconserved features in the catalytic domain as well as the 
regulatory mechanisms (68, 69). Exploiting these nonconserved features of LYP as well 
as mimicking the regulatory mechanisms can help in targeting LYP selectively over other 
homologous PTPs. Therefore a detailed understanding biological regulation, structural 
features and interaction between the substrates and LYP is essential for developing potent 
and selective chemical probes for LYP. 
 
1.4.1 Biological regulation of lymphoid tyrosine phosphatase activity 
The activity of LYP is regulated through several different mechanisms including 
posttranslational modifications, regulatory domains, restricted subcellular localization 
and reversible oxidation (48, 50, 55, 70). LYP may be regulated by phosphorylation of a 
serine residue in the catalytic domain (48). Serine35 in the catalytic domain of LYP is 
phosphorylated by protein kinase C (PKC) and the resulting phospho-LYP shows 
impaired dephosphorylation of endogenous LYP substrate, Lck. The catalytic domain of 
LYP interacts with the proximal interdomain and this intramolecular interaction has been 
shown to inhibit the catalytic domain (50). Another proposed mechanism of regulation of 
LYP is spatial control of its activity through interaction with the kinase CSK (55). It has 
been proposed that under the resting conditions in T cells, LYP forms a complex with 
CSK, thereby physically separating LYP from its substrates present in the lipid rafts 
(Figure 1.3). When TCR signaling is initiated, the resulting signaling cascade eventually 






membrane. The substrates of LYP including Lck and ZAP-70 are a part of this TCR 
signalosome. TCR stimulation also leads to dissociation of LYP from CSK and recruits 
LYP to TCR signalosome in the lipid rafts. Once in TCR signalosome, LYP can 
dephosphorylate its substrates turning off TCR signaling. It has also been proposed that 
the gain of function variant, LYP-W620, cannot bind to CSK and therefore has 
unregulated access to its substrates even under resting conditions (55). However, concrete 
evidence showing that LYP does not have access to its substrate when in the cytoplasm is 
lacking. Another mechanism of LYP regulation is through oxidation of the catalytic 
cysteine residue with oxidizing agents such as H2O2 and NO, rendering it non-
nucleophilic and therefore, inactive (71-74). A crystal structure of the catalytic domain of 
LYP reveals that this enzyme contains two additional cysteine residues within disulfide 
bonding distance from the catalytic C227: C129 and C231. Cysteine231 is a part of the P-
loop while C129 is a backdoor cysteine residue (75). These additional cysteine residues 
are not present in other PTPs, barring other members of NT4 subfamily: PTP-PEST and 
BDP1. In vitro, the presence of excess of H2O2 causes the C227 residue to form a 
disulfide bond with C129 that reversibly inactivates the enzyme. The presence of these 
additional cysteine residues presents a unique opportunity for targeting LYP selectively 
over other homologous PTPs. 
 
1.4.2 Structural features of the lymphoid tyrosine phosphatase 
Apart from the regulatory mechanisms, interaction of substrates with conserved 
and nonconserved features of the catalytic domain play a crucial role in determining 






necessary in order to appreciate this. A ribbon diagram of LYP highlighting the key 
structural features is shown in Figure 1.5. The pY binding site or P-loop (residues 226-
233) forms a deep pocket on the surface of LYP and has a strong positive charge. The pY 
recognition loop (residues 54-60) contributes to the selective recognition of pY over pS 
and pT. The other conserved features in the catalytic domain include the Q-loop (residues 
274-301) and β3-β4 loop (residues 131-139), which are important in interactions with the 
pY residue of the substrate. One of the key substrate recognition features of PTPs is the 
dynamic opening and closing of the WPD loop (residues 193-204 in LYP). The closing 
of WPD loop over the active site is essential for the phosphatase activity, and, therefore, 
the closed state of WPD loop leads to the active form while the open state of WPD loop 
leads to the inactive form of PTPs. In LYP crystal structure 2P6X shown in Figure 1.5, 
the WPD loop is in an inactive, atypically open state. A highly nonconserved 
hydrophobic pocket adjacent to the WPD loop is exposed only in the open state of the 
WPD loop of LYP (55). Locking the WPD loop in the open state through interactions 
with this hydrophobic pocket adjacent to the WPD loop provides an attractive approach 
for selective inactivation of LYP. Besides the fairly conserved features, highly non-
conserved features like secondary substrate binding pockets are also found in some of the 
PTPs including PTP1B and LYP. The secondary substrate binding pocket in PTP1B has 
been exploited previously for the development of selective inhibitors of PTP1B and 
TCPTP (76-78). The second-site-loop in LYP, the LYP insert, is highly nonconserved 
and is present only in the other members of NT4 subfamily of classical PTPs, PTP-PEST 
and BDP1. Therefore, the interactions with the LYP insert are also likely to provide 





















Figure 1.5. Crystal structure of LYP (PDB entry 2P6X). The regions surrounding the P-
loop (red) are highlighted in gold (pY recognition loop, Q-loop, WPD loop and β3-β4 










1.4.3 Using peptides to achieve selectivity 
Although LYP has been identified as an intriguing therapeutic target for 
autoimmune disorders, its precise biological functions in signaling cascades and cellular 
physiology are still poorly understood (79). It is quite likely that LYP may act on one or 
more unidentified substrates apart from Lck and ZAP-70 in TCR signaling, while its 
substrates and precise role in mast cell signaling is completely unknown. Therefore, it is 
essential to develop a full repertoire of LYP substrates and the signaling cascades 
modulated by LYP (80).  
Peptides containing pY are the most accurate mimics of the biological substrates 
of the PTPs. For example, ARLIEDNE-pY-TAREG-NH2 (peptide 1) is a peptide 
sequence based on the amino acid residues flanking Lck pY394, a known physiological 
substrate of LYP, and it is the most accurate mimic of the biological substrate of LYP 
(38, 52). Substrate library screening approaches have been employed for screening 
combinatorial peptide libraries with the aim of identifying unknown substrates of LYP as 
well as peptide sequences that will target LYP potently and selectively (80, 81). These 
studies have established that LYP shows distinct amino acid preferences for each position 
flanking pY in its substrate establishing the importance of the interaction between LYP 
surface with these amino acids flaking pY in the substrate. A couple of the best peptide 
substrates of LYP identified from this study, YGEE-pY-DDLY and DGEE-pY-DDPF, 
have been cocrystallized with catalytic domain of LYP (80). These cocrystal structures 
have established that these peptide substrates interact with the active site as well as the 






However, crystallography can provide only a snapshot of the enzyme-peptide 
interaction and cannot provide the fluxional details of this dynamic interaction. 
Therefore, we decided to investigate the dynamic and transient interactions between LYP 
and its peptide substrate. To understand how the selectivity is derived through 
interactions with nonconserved features of catalytic domain, Dr. Nadeem Vellore from 
Dr. Riccardo Baron’s laboratory simulated the interaction between LYP and peptide 1, 
the accurate mimic of the biological substrate of LYP, using computer modeling and 
molecular dynamics (MD) simulations (Figure 1.5). Dr. Vellore found that peptide 1 
shows high conformational diversity, and samples transient binding modes throughout 
the simulation, as summarized in Figure 1.6. As expected, the pY residue was found to 
hydrogen bond with S228, A229 and R233 of the P-loop, K138 of the β3-β4 loop and 
Q274 residue of the Q-loop.  A detailed list of all hydrogen bonding interactions between 
peptide 1 and LYP are documented in Table 1.1. Overall, pY forms at least one hydrogen 
bond throughout the 150 ns ensemble (98% of time). The first five residues of the N-
terminus (ARLIE) and the two residues from the C-terminus region (RE) of peptide 1 
showed b-turn propensity (~10% and ~20% time occurrences). The N-terminal ‘AR’ 
residues of the peptide were found to be solvated during most of the simulation time with 
no dominant and/or specific interactions with the protein. The C-terminus of the peptide 
was involved in interacting with the Q-loop and partially with WPD loop, as displayed in 
Figure 1.6. During the course of the simulation, peptide 1 made favorable contacts with 
the P-loop and pY recognition loop and showed little interaction with the LYP-specific 
insert. Taken together, MD simulation data confirmed that the peptide interacts with the 









Figure 1.6. Dynamics of the LYP-peptide 1 bound ensemble as revealed by 150 ns of 
molecular dynamics simulation. The Lyp surface is shown (gray) together with peptide 1 
(licorice model; red tube: backbone). Key residues making hydrogen bonds with the 
peptide at least 5% of the time during the simulation are highlighted using van der Waals 
spheres and color-coding depending on residue type. Key LYP-peptide 1 snapshots 
correspond to simulation periods of (a) 0 ns (b) 70 ns and (c) 150 ns. (d) Ensemble of 











Table 1.1. List of residues involved in the intermolecular hydrogen bonding between the 
peptide 1 and LYP from the 150 ns MD simulation. Only the residues involved in 
hydrogen bonding at least 5% of time are reported. 
 
Peptide 1 LYP (Percentage) 
E5 K136 (64%) 
D6 K61 (7%) 
K136 (6%) 
N7 K61 (24%) 
R59 (18%) 





T10 Q274 (7%) 
R12 E133 (14%) 
E277 (9%) 
E13 Q276 (6%) 
 
based on this discussion that peptides can target LYP potently and selectively through 
their interactions with both conserved and nonconserved features on the LYP surface. 
 
1.5 Summary 
PTPs are highly specific and tightly regulated enzymes that play crucial roles in 
several biological processes and are important therapeutic targets. LYP is an interesting 
therapeutic target for treatment of several autoimmune disorders including anaphylaxis. 
However, precise biological functions of LYP in signaling cascades and cellular 
physiology are still poorly understood. Chemical probes can be beneficial for addressing 






therapeutic inhibition of LYP. For their optimum utility, these chemical probes need to be 
selective for LYP. Crucial insights about selective targeting of LYP can be gained from 
studying how LYP demonstrates substrate specificity in vivo. The substrate specificity of 
LYP in vivo can be attributed to the interactions of the substrates with the nonconserved 
features of LYP and to the biological regulation of LYP. Exploiting these interactions 
with nonconserved features of LYP catalytic domain as well as mimicking the regulatory 
mechanisms can help in targeting LYP selectively over other homologous PTPs. Peptides 
are arguably the most accurate mimics of biological substrates of LYP, which can target 
both the conserved and nonconserved features of LYP. Therefore, we suggest that 
peptides can play a huge role in developing chemical probes for LYP and other PTPs. 
 
1.6 Perspective 
The broad aim for this dissertation is to develop potent and selective inhibitors of 
LYP, which can find utility as chemical probes. As I have discussed earlier, LYP exhibits 
high substrate specificity in vivo that can be attributed both to the nonconserved features 
in the catalytic domain as well as the regulatory mechanisms. Therefore, we have 
hypothesized that exploiting these nonconserved features of LYP as well as mimicking 
the regulatory mechanisms can help improve LYP selectively over other homologous 
PTPs. Towards this end, we have taken several approaches for identifying potent and 
selective inhibitors of LYP that involve use of either peptides for exploiting non-
conserved features of LYP or mimicry of a regulatory mechanism of LYP. Each of these 
approaches is discussed below in brief with the aim of introducing the following chapters 






Assay design is an important variable that influences the identification of 
biologically relevant inhibitors in a screen. The choice of substrate in the PTP inhibitor 
screen is crucial in guiding the outcome of the screen. Small molecule pY mimics bind 
only to the active site of LYP and, therefore, cannot accurately mimic biological 
substrates of LYP. Peptides are the accurate mimics of biological substrates of LYP, and 
they can target both the conserved and nonconserved features of LYP. Therefore, we 
hypothesized that using a peptide substrate can help in identifying more biologically 
relevant hits. With the aim of comparing the utility of a peptide substrate and a small 
molecule substrate as well as finding potent and selective LYP inhibitors, we have 
screened several compound libraries against LYP using both substrates. The results of 
this exercise are discussed in detail in Chapter 2.  
We believe that potent inhibitors of LYP can be developed by mimicking the 
mechanisms of biological regulation. LYP is regulated by oxidation of the low pKa 
catalytic cysteine residue in the active site. We decided to take advantage of oxidation of 
the catalytic cysteine residue of LYP to identify thiuram disulfides as pseudo-irreversible, 
covalent inhibitors of LYP that inhibit LYP by the formation of mixed disulfides. The 
results of this study are discussed in detail in Chapter 3.  
Activity-based probes (ABPs) can serve as effective tools for addressing 
important biological questions pertaining to LYP. When developing ABPs for LYP, 
potent and selective covalent inhibitors of LYP must first be developed. Nonselective 
covalent inhibitors of PTPs usually contain pY-mimicking, cysteine-reactive electrophilic 
moiety. Peptide sequences can target LYP potently and selectively. We have combined 






develop peptide-based covalent inhibitors of LYP. The detailed results of this study are 
discussed in Chapter 4.  
 
1.7 Experimental section 
1.7.1. Computational modeling  
An initial model of the human LYP protein was prepared with the Schrödinger 
Protein-Preparation wizard (82) based on PDB entry 2P6X (resolution 1.90 Å) assuming 
an apparent neutral pH (68). An initial model for peptide 1 (ARLIEDNEpYTAREG) was 
prepared in which the pY moiety was created with tLEaP program (83), all the backbone 
dihedrals were set in trans configuration, and the N-and C-termini were capped with 
acetyl and methylamine groups, respectively. The initial model was generated by placing 
the P atom of the phosphotyrosine residue at a distance of 5 Å from the C227 Cα atom. 
The configuration of peptide 1 was selectively minimized using the ‘relax’ procedure in 
xLEaP by constraining the position of the protein atoms in the system.  
 
1.7.2 Molecular dynamics simulations  
The AMBER12 simulation package was used for preparation of the system. The 
GPU version of PMEMD was used for trajectory production (84, 85). The Amber ff99SB 
force field (86) was employed for standard protein and peptide parameters. Parameters 
for the nonstandard phosphotyrosine residue were taken from the literature (87). The 
initial model was solvated using a pre-equilibrated box of TIP3P water molecules (88) 
maintaining a minimum distance of 15 Å between any protein atom and the box edges. 






17,716 water molecules and 5 Cl- ions added at random positions to neutralize the overall 
system. 
The LYP-peptide system was minimized using the steepest descent algorithm 
(500 steps) and the conjugate gradient algorithm (500 steps). During the minimization 
protocol, the protein heavy atoms were kept close to their position in the X-ray model by 
an atom-positional harmonic restraining potential (total force constant of 250 
kcal/mol/Å2) in order to eliminate any strain between protein and solvent interactions. 
During the next standard stages of heating, equilibration, and production simulation run, 
Langevin dynamics (89) was used as the integrator with a collision frequency (γ) of 2   
ps-1. All the bonds involving hydrogen atoms were constrained using the SHAKE 
algorithm (90). The Particle Mesh Ewald approximation (91) was used for full 
electrostatic treatment (real space interactions truncated at 10 Å). In the initial stage of 
heating, 50 ps of the restrained MD simulation was performed with the protein heavy 
atoms restrained (total force constant of 10 kcal/mol/Å2; 1 fs time step up to 200 K). 
Further, 100 ps of heating was performed with no restrains using canonical (NVT) 
ensemble to a final temperature of 300 K. The equilibration simulation was performed for 
5 ns using a 2 fs time step and the pressure was maintained at 1 atm using an isotropic 
weak-coupling algorithm (92). The system was simulated for 150 ns at 300 K, saving MD 
snapshots every 10 ps for analysis. 
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SUBSTRATE SELECTION INFLUENCES HIT IDENTIFICATION 
































2.1 Introduction and preliminary studies 
Tyrosine phosphorylation is one of the most important cellular posttranslational 
modifications, generating recognition motifs for protein-protein interactions, modulating 
enzyme activity and controlling many aspects of cell growth, differentiation, metabolism, 
migration and survival (1, 2). The enzymes responsible for modulating tyrosine 
phosphorylation, PTPs and PTKs, have been recognized as relevant therapeutic targets 
for the treatment of diabetes, cancer and autoimmunity, but only PTK inhibitors have 
made it to the clinic thus far (3, 4). Considerable effort has been devoted to the 
development of potent, selective PTP inhibitors for use as chemical probes and potential 
therapeutic leads, but there are still several challenges in the field (5-10). Specifically, 
many of the PTP inhibitors identified to date are phosphotyrosine mimetic compounds 
with poor bioavailability. In addition, due to the highly conserved nature of the PTP 
active site, inhibitors that target the pY binding pocket tend to inhibit many members of 
the PTP family of enzymes and selectivity has been difficult to obtain. However, similar 
challenges have been resolved in the design of therapeutically relevant PTK inhibitors, 
and it is likely that with the right set of tools for inhibitor screening, PTP-targeted 
therapeutics can be developed as well. 
The human genome contains a total of 107 genes encoding a PTP domain; 81 of 
these genes are predicted to encode an active PTP domain (11). The PTP catalytic 
domain is highly conserved and contains the PTP signature motif, (H/V)C(X)5R(S/T), 
which includes the catalytic cysteine residue and the arginine residue which plays a key 
role in  recognizing the pY moiety of the substrate (12). However, PTPs exhibit diverse 
surface features outside the pY binding pocket that remain largely unexplored in inhibitor 
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development (4, 13). An exception is the secondary substrate-binding pocket, which has 
been exploited for the development of selective inhibitors of PTP1B and TCPTP (14-16).  
Recently, the lymphoid tyrosine phosphatase (LYP or PTPN22) has been 
recognized as an intriguing therapeutic target because of its association with human 
autoimmunity (17-21). LYP is a negative regulator of T-cell receptor signaling (22). A 
single nucleotide polymorphism (SNP) (C1858T) in the PTPN22 gene results in a gain of 
function variant of LYP that is associated with an increased risk of autoimmune disorders 
including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, Grave’s 
disease and myasthenia gravis (23-25). Correspondingly, the G788A SNP in the PTPN22 
gene leads to a loss of function variant that is protective against systematic lupus 
erythematosus (26). Furthermore, the mouse ortholog of LYP (PEP) is a positive 
regulator of anaphylaxis in mice and both genetic and chemical knockdown of LYP 
(PEP) activity has been shown to alleviate anaphylaxis in mice (27). Taken together, 
these findings reinforce the importance of LYP in the immune response. While inhibition 
of LYP activity could be therapeutically beneficial, inhibition of other T-cell derived 
PTPs is likely to be detrimental. Therefore, if therapeutic LYP inhibitors are to be 
developed, the issue of PTP selectivity must be addressed. 
Assay design is an important variable that influences the identification of 
biologically relevant inhibitors in a screen. We (18, 28) and others (29) have 
hypothesized that the choice of substrate in the PTP inhibitor screen is crucial in guiding 
the outcome of the screen. PTPs catalyze conversion of pY (Figure 2.1) to tyrosine (Y) 












Figure 2.1. Colorimetric and fluorogenic PTP substrates.  
 
formation of either of the product of this reaction Pi or tyrosine. The released Pi can react 
readily with molybdenum(VI) to form phosphomolybdate. Malachite green can form a 
green colored complex with phosphomolybdate at low pH. Therefore, by measuring the 
absorption at 620-660 nm, amount of Pi can be determined which is a direct indicator of 
the PTP activity (30). However, malachite green assay is a discontinuous assay and 
therefore, measuring kinetics with this assay is laborious. Peptides containing pY are the 
most accurate mimics of the biological substrates of the PTPs and therefore, monitoring 
the dephosphorylation of pY peptides gives most optimum measure of PTP activity. 
Products of dephosphorylation of pY peptides, the corresponding Y peptides show 
increased absorption at 280 nm and increase in fluorescence at 305 nm and therefore, 
PTP activity can be monitored by measuring the increase in absorption or fluorescence. 


























very small and in this region of spectrum the background, due to interference caused even 
by buffer components, is usually very high. Therefore, this assay has a low sensitivity.  
To overcome these problems, traditional assays for PTP inhibitor screening use 
nonpeptidic pY mimetic substrate such as p-nitrophenyl phosphate (pNPP), 3-O-
methylfluorescein phosphate (OMFP), 4-methylumbelliferone phosphate (MUP), and 
6,8-difluoro-4-methylumbelliferone phosphate (DiFMUP) (Figure 2.1) (31). One of the 
most commonly used substrates of PTPs, pNPP itself is colorless. However, upon 
hydrolysis it forms p-nitrophenol, which at alkaline pH ionizes to bright yellow phenolate 
ion that can be detected by measuring absorbance at 405 nm. OMFP is a fluoregenic 
substrate of phosphatases that upon hydrolysis forms 3-O-methylfluorescein (OMF). The 
formation of OMF can be monitored at emission wavelength of 528 nm upon excitation 
at 485 nm. Other fluoregenic substrates for PTPs include MUP and DiFMUP. These 
substrates are slightly fluorescent themselves but upon dephosphorylation produce highly 
fluorescent 4-methylumbelliferone (MU) and 6,8-difluoro-4-methylumbelliferone 
(DiFMU), respectively. The formation of MU and DiFMU can be monitored at emission 
wavelength of 455 nm upon excitation at 360 nm. However, pNPP and DiFMUP are 
highly activated substrates due to the presence of strong electron withdrawing groups and 
therefore, both these substrates are susceptible to autohydrolysis resulting in high 
background. MUP is not an activated substrate and therefore it mimics pY more 
accurately than pNPP and DiFMUP. However, all these nonpeptidic pY mimetic 
substrates, owing to their size, predominantly only interact with the active site of the 
PTPs. These small molecule substrates, therefore, cannot accurately mimic biological 
substrates of PTPs like pY peptides. It has also been suggested that a substrate capable of 
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interacting with sites on the enzyme outside of the pY binding site would be superior to a 
simple small molecule pY mimetic substrate in identifying hits with biological activity 
and selectivity for the enzyme of interest (18, 29). Our collaborators have shown in 
Chapter 1 through molecular dynamics (MD) simulation that peptide substrates interact 
with both conserved and nonconserved features of LYP. Together with the known 
problems associated with the spectroscopic properties of pY peptides, it is clear that an 
ideal substrate should combine the utility of the fluoregenic pY mimics with the bio-
mimetic properties of the peptides. 
With this in mind, our group has developed a phosphorylated coumaryl 
aminopropionic acid (pCAP, Figure 2.1). This phosphotyrosine mimetic amino acid can 
be readily incorporated into a peptide chain and, upon PTP-mediated dephosphorylation, 
undergoes a large increase in fluorescence, providing a facile, high-throughput assay for 
PTP activity (18, 32). For example, by incorporating pCAP in the place of pY in a 
peptide sequence based on the amino acid residues flanking Y394 of Lck, a known 
physiological substrate of LYP (25, 33), peptide 1 (Figure 2.2), an excellent substrate for 
LYP was obtained (18). In order to establish the similarity of peptide 1 with the 
biological substrate of the LYP, we decided to compare the kinetic properties of peptide 
1 with the most accurate mimic of biological substrate of LYP, peptide 1A (Figure 2.2). 
LYP showed similar Michaelis binding constant (Km) and turnover number (kcat) within 
errors for peptide 1 and peptide 1A (Table 2.1). Therefore, we think that peptide 1 can 










Figure 2.2. Peptides based on sequence of amino acid residues flanking Lck Y394, a 
biological substrate of LYP. 
 
Table 2.1. Kinetics of LYP mediated dephosphorylation of peptides based on sequence 
of amino acid residues flanking Lck Y394, a biological substrate of LYP. 
Peptide kcat, x103 (s-1) Km, x10-4 (M) kcat/Km, x107 (M-1s-1) 
Peptide 1 5.4 ± 1.0 2.0 ± 0.6 2.7 

















Peptide 1 Peptide 1A
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With the aim of qualitatively comparing the different PTP assays, we calculated 
the signal to background ratio (S/B) and the signal to noise ratio (S/N) for these assays 
(Table 2.2). The working concentration of the substrate used was selected to get the S/B 
roughly around 10, with maximum substrate concentration used fixed at 500 µM. A high 
concentration of peptide 1A was required to get reasonable S/B in malachite green assay. 
However despite low S/B, this assay was still found to be very sensitive owing to the 
very little variability in the background. Next, monitoring increase in fluorescence upon 
dephosphorylation of peptide 1A was found to be a low sensitivity assay, primarily 
owing to the high background values in this region of the spectrum. Requirement of high 
concentrations of peptide 1A for these assays along with the low sensitivity of the 
flurescence assay and tedious nature of the malachite green assay warrant development of 
a better approach towards assaying LYP activity.  
Among the fluoregenic substrates of PTPs, MUP showed fairly low S/B and but 
reasonable sensitivity at 500 µM concentration. This finding indicates that a much higher 
concentration of MUP is required to render the assay sensitive. On the other hand, 
DiFMUP was found to be an excellent substrate that showed very high values for S/B and 
S/N even at low to submicromolar concentration. Next, we tested the sensitivity of the 
LYP assay using Peptide 1 as a substrate. Peptide 1 is a fluoregenic substrate that 
combines the desirable properties of peptide 1A and MUP. Assay using low micromolar 
concentration of peptide 1 as a substrate showed much better S/B and S/N than assays 
for both peptide 1A and MUP. Therefore, we hypothesized that owing to its resemblance 
to the biological substrate of LYP and fluoregenic property, peptide 1 will be more 
useful in a screen for LYP inhibitors in identifying more biologically relevant hits. 
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Table 2.2. Qualitative comparison of some of the important PTP assays. All assays were 
carried out using final concentration of 5 nM LYP, preactivated with 1 mM DTT in the 
same activity buffer described in the experimental section.  
 
Substrate Method and readout [Substrate] S/B S/N 
Peptide 1A 
Malachite Green Assay 
Absorption 620 nm 
250 µM 







Excitation 280 nm 
Emission 305 nm 
500 µM 2 12 
MUP 
Fluorescence 
Excitation 360 nm 
Emission 455 nm 
500 µM 6.5 94 
DiFMUP 
Fluorescence 
Excitation 360 nm 









Excitation 360 nm 















In the past 6 years, several LYP inhibitors with high nanomolar to low 
micromolar potencies were reported in the literature (Figure 2.3). A benzofuran salicylic 
acid derivative (I-C11) was identified from a library of 80 compounds synthesized using 
click chemistry (21). A cocrystal structure of I-C11 and LYP revealed that benzofuran 
salicylic acid core occupied the LYP active sight while the naphthalene ring occupied the 
neighboring hydrophobic pocket. This bidentate salicyclic acid derivative showed some 
selectivity for LYP over other T-cell derived PTPs, but only a little selectivity was 
observed over PTP1B and no information about PTP-PEST inhibition was reported. 
Thiazolidine-2,4-diones (TZDs) and 2-thiaoxothiazolidin-4-ones were identified as LYP 
inhibitors from a screen of the NIH molecular libraries using DiFMUP (20). Further SAR 
studies on the hits led to identification of TZD 8P as a submicromolar inhibitor of LYP 
(Figure 2.3). Compounds in this series also owed their potent inhibitory activity to the 
presence of salicylate moiety. However, no information was provided about the 
selectivity or the cellular activity of these inhibitors. WPD loop of LYP is known to be 
highly mobile and it keeps switching between an active closed conformation and an 
inactive open conformation. With the aim of identifying inhibitors that bind to and 
stabilize the inactive open conformation of LYP, a virtual ligand screen was performed 
with this open conformation of LYP (34). Further experimental evaluation of the hits 
from this virtual screening exercise, helped in identifying a series of 2-benzamidobenzoic 
acid derivatives as submicromolar inhibitors of LYP but no selectivity or cellular activity 


















Figure 2.3. LYP inhibitors reported in the literature. 
 
Auranofin and other gold(I) compounds have been used in the treatment of 
autoimmune disorders for decades but their biological targets are not completely known. 
Owing to the thiophilicity of gold, these compounds have been shown to inhibit cysteine 
proteases such as cathepsins and thioredoxin reductase (35-38). Our laboratory has 
demostrated that the gold-based antiarthitic drug auranofin inhibits PTP-PEST activity 
20-fold better than LYP activity and several gold(I) N-heterocyclic carbenes (gold NHC, 













































IC50 = 2.9 µM
TZD 8P
IC50 = 0.39 µM
Benzamidobenzoic acid
IC50 = 0.95 µM Gold NHC
IC50 = 10 µM
Gold phosphine C28
IC50 = 3.5 µM
LTV-1
IC50 = 0.508 µM
Allosteric Inhibitor
IC50 = 5.3 µM
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inhibition of LYP, they do not show selectivity for LYP inhibition over PTP-PEST, 
HePTP and PTP1B. Our lab also identified a related gold(I) phosphine complex with up 
to 25-fold selectivity for LYP over PTP-PEST from a library of 40 different gold(I) 
phosphines, providing perhaps the best evidence inhibitors that show selectivity for LYP 
over PTP-PEST can be developed (18).  
An allosteric inhibitor of LYP was identified from a screen of a 4000 compound 
library. The mode of inhibition for this inhibitor was found to be noncompetitive. This 
inhibitor was shown to bind to a hydrophobic patch located outside the active site of 
LYP. It showed excellent cellular activity and it was shown to increase T-cell signaling in 
primary T-cells. Although this inhibitor showed some selectivity for LYP over the 
homologous PTPs, selectivity over PTP-PEST was not obtained. LTV-1 was identified 
through high-throughput screening effort. Impressively, this compound showed >200-
fold selectivity for inhibition of LYP over PTP-PEST but showed only about 3-fold 
selectivity for LYP over TCPTP and PTP1B.  
Although these LYP inhibitors have proven useful as chemical probes of the 
biological activity of LYP, greater potency and selectivity must be achieved in order to 
obtain a widely applicable probe. With this in mind and with the aim of establishing the 
utility of peptide 1, we screened compound libraries for LYP inhibition using peptide 1 
and a small molecule pY mimic, DiFMUP, as substrates. 
 
2.2 Results and discussion 
The screening conditions were first optimized for each substrate to achieve 
acceptable assay performance, sensitivity and robustness. The Z´ value of 0.68 for 
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peptide 1 and 0.81 for DiFMUP indicated excellent performance in the screening assays. 
The signal to background ratio (S/B) of ~10 and ~128, and the signal to noise ratio (S/N) 
of ~235 and  ~1325, for peptide 1 and DiFMUP assays, respectively, indicate sensitive 
and robust assay conditions. To test the hypothesis that substrate selection can influence 
screening results, two, parallel, medium-throughput experimental screens of the Spectrum 
collection, a commercially available collection of 2000 compounds, were carried out, one 
using peptide 1 as the substrate and the second using DiFMUP. The spectrum collection 
consists of FDA approved drugs (50%), other bioactive compounds that have either not 
reached the developmental stages or been dropped for toxicological or other reasons 
(20%) and natural products with known and unknown biological activity isolated from 
variety of natural sources (30%). The compounds in this library are selected to provide a 
wide range of biological activities and structural diversities. Extensive studies have 
already been carried out with the known FDA approved drugs as well as several other 
bioactive compounds and natural products in this library to ensure their viability as 
therapeutics in humans. The availability of adequate information about the SAR of these 
compounds also means that the optimization of the hits from the library screening is 
relatively easy. Libraries of this kind have been used to obtain hits for many different 
applications including cancer, malaria and amebiasis (35, 39-41). Taken together, 
screening of small, focused libraries of chemically diverse, drug-like compounds can 
accelerate the drug discovery process by finding new applications of known compounds 
(35, 39, 41). The chemical and biological diversity of this library, together with the 
knowledge that several drugs and natural products are already known to inhibit different 
PTPs (7), warrant the possibility of finding new classes of compounds that are previously 
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unknown to inhibit PTPs. Besides this, identifying PTP inhibitors from a library of drug-
like compounds also validates the utility of peptidic substrates in PTP inhibitor 
screenings.  
The results of the initial screen using peptide 1 as the substrate are shown in 
Figure 2.4. The most potent hits, along with hits that showed significantly different 
inhibition of LYP activity depending on whether peptide 1 or DiFMUP was used as the 
substrate were selected for follow-up. The initial cut-off for the hits was set to inhibition 
of at least 30% of LYP activity at 10 µM. Although about 10% of the compounds 
fulfilled this criterion, the hit rate was then brought down to 4% (a total of 80 
compounds) by cherry-picking the hits for the follow-up studies. The most potent hits, 
along with hits that inhibited LYP activity significantly better or worse with DiFMUP as 
a substrate than with peptide 1 as a substrate, were selected in the cherry picking. These 
top 80 compounds (Table 2.3) were rescreened against LYP and counter-screened against 
PTP-PEST at 5 µM and 50 µM concentrations. Results are shown in Figure 2.5 
(rescreening with LYP), Figure 2.6 (counter-screening with PTP-PEST) and Figure 2.7 
(selected results from rescreening with LYP). A few previously known PTP inhibitors 
including suramin (compound 1), purpurin (compound 5) and aurothioglucose 
(compound 9) came up as top hits in both of our screens, validating our screening 
protocol (7, 19, 42-44). However, most of the top hits were compounds that had not been 
identified as phosphatase inhibitors previously. While some of the hits were equally 
potent inhibitors of LYP activity regardless of substrate used, others inhibited LYP 
activity on peptide 1 significantly better than on DiFMUP or vice versa (Figure 2.7, 













Figure 2.4. Results from the Spectrum collection screen for LYP inhibitors using peptide 
1 as the substrate. Each compound is represented by its position in one of the 25 96-well 
plates in the collection. Compounds showing significant inhibition at 10 µM are indicated 
as red squares, compounds showing no inhibition are indicated as green squares, 
compounds with intermediate inhibitory properties are shown in the intermediate colors 














1 COUMARIN 41 CLOFAZIMINE 
2 AMPHOTERICIN B 42 CAPERATIC ACID 
3 CEFOTAXIME SODIUM 43 XANTHONE 
4 CYCLIZINE 44 IRIGENOL 
5 PYRITHIONE ZINC 45 GINKGOLIC ACID 
6 ESTRADIOL CYPIONATE 46 LARIXOL ACETATE 
7 GUANETHIDINE SULFATE 47 2',2'-BISEPIGALLOCATECHIN DIGALLATE 
8 HALOPERIDOL 48 OSAJIN 
9 HEXACHLOROPHENE 49 3β-HYDROXY-DEOXODIHYDRODEOXYGEDUNIN 
10 HYDROCORTISONE ACETATE 50 PURPURIN 
11 INOSITOL 51 HEMATEIN 
12 MERBROMIN 52 ELLAGIC ACID 
13 FLUFENAMIC ACID 53 PRIMULETIN 
14 FENSPIRIDE HYDROCHLORIDE 54 7,4'-DIHYDROXYFLAVONE 
15 RONIDAZOLE 55 3',4'-DIMETHOXYFLAVONE 
16 TRANEXAMIC ACID 56 JUGLONE 
17 CEPHALEXIN 57 CAMPTOTHECIN 
18 CEFSULODIN SODIUM 58 EMBELIN 
19 SURAMIN 59 EPIGALLOCATECHIN 3,5-DIGALLATE 
20 VIGABATRIN 60 3,4'-DIHYDROXYFLAVONE 
21 THIRAM 61 HARMALOL HYDROCHLORIDE 
22 IOPANIC ACID 62 OXONITINE 
23 CEFTIBUTEN 63 AESCULIN 
24 SERTRALINE HYDROCHLORIDE 64 5,7-DIHYDROXYISOFLAVONE 
25 CHLOROPHYLLIDE Cu COMPLEX Na SALT 65 THEAFLAVIN 
26 METHYLDOPATE HYDROCHLORIDE 66 4-NONYLPHENOL 
27 BENZOXYQUINE 67 5beta-12-METHOXY-4,4-BISNOR-8,11,13-PODOCARPATRIEN-3-ONE 
28 GEMIFLOXACIN MESYLATE 68 L-BUTHIONINE SULFOXIMINE 
29 PRAVASTATIN SODIUM 69 METHYLPREDNISOLONE SODIUM SUCCINATE 
30 DESOXYMETASONE 70 2,4-DINITROPHENOL 
31 BENZBROMARONE 71 EFAROXAN HYDROCHLORIDE 
32 DIMERCAPROL 72 NEORUSCOGENIN 
33 METHYLBENZETHONIUM CHLORIDE 73 PROTOPORPHYRIN IX 
34 CHLOROGUANIDE HYDROCHLORIDE 74 PRIDINOL METHANESULFONATE 
35 MOXIDECTIN 75 BENZANTHRONE 
36 PHYTONADIONE 76 NIPECOTIC ACID 
37 BETAMETHASONE ACETATE 77 AZOBENZENE 
38 BROMPERIDOL 78 HYDROXYTACRINE MALEATE 
39 OXANTEL PAMOATE 79 ANTHRACENE-9-CARBOXYLIC ACID 




















Figure 2.5. Secondary screen showing the ability of the top 80 hits from the Spectrum 
library screen to inhibit LYP activity at (A) 5 µM and (B) 50 µM using peptide 1 (black 


















































Figure 2.6. Secondary screen showing the ability of the top 80 hits from the Spectrum 
library screen to inhibit PTP-PEST activity at (A) 5 µM and (B) 50 µM using peptide 1 












































Figure 2.7. Select hits from the rescreening of top 80 compounds from the Spectrum 
collection at 50 µM using peptide 1 (black bars) or DiFMUP (grey bars) as the substrate.  
 
Table 2.4. Hit validation and counter screening of selected hits from the Spectrum library 


















1 Suramin 25.0 ± 0.3 3.0 ± 0.1 27 ± 3 11 ± 1 30 ± 3 42 ± 5  
2 Caperatic acid 12 ± 1 6.5 ± 0.7 NA NA NA NA 
3 Cefotaxime 40 ± 2 17 ± 2 70.0 ± 0.8 NA NA NA 
4 Sertraline 44 ± 3 150 ± 10 55 ± 5 NA 110 ± 5 80 ± 4 











NA 0.50 ± 0.03 
7 Harmalol HCl 15 ± 2 7.0 ± 0.8 35 ± 2 35 ± 2 NA 14 ± 1 
8 Benzanthrone 28 ± 1 13 ± 1 > 150 > 150 35 ± 5 > 150 
9 Aurothioglucose 4.0 ± 0.1 1.5 ± 0.1 8 ± 1 5 ± 0.8 NA NA 



















determining their IC50 values against LYP using both DiFMUP and peptide 1 in 
secondary dose-response screens. The selectivity of these top hits was profiled by 
determining their IC50 values against PTP-PEST, HePTP and CD45 (Figure 2.8, Table 
2.4). 
Several of the top hits were flat, rigid, aromatic compounds with negative charge, 
mimicking the pY moiety. Quite a few of the hits contained a coumarin, flavone or 
polyphenolic moiety, features that are also known to mimic the pY residue. Metal 
containing compounds including aurothioglucose and merbromin were also found among 
the most potent LYP inhibitors, which may be attributed to the thiophilicity of gold and 
mercury, respectively. More unexpected, however, was the result that several 
cephalosporin derivatives inhibit LYP activity. This may be attributed to the carboxylate 
functionality present in many of the cephalosporins, including cefotaxime. While some of 
the top hits bear a resemblance to compounds known to frequent hitting false positives 
showing promiscuous activity in many assays by virtue of aggregate formation (45), it 
has been shown that nonspecific inhibition by aggregates can be eliminated by the 
addition of a detergent to the assay buffer (46, 47). Our assay buffer contained 0.01% of a 
nonionic detergent to ensure that nonspecific aggregates were not formed. As evidence 
that our screens were designed to avoid false positives due to aggregation, known 
aggregate forming compounds in our library (such as quercetin) were not hits with either 
substrate (45). On the contrary, suramin, once falsely thought to be a nonspecific 
aggregate forming inhibitor, was found to inhibit LYP (45). Although suramin is known 

























































































































(9) Aurothioglucose (10) Sennoside A
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its targets through key interactions with the proteins. For example, it has also been shown 
to be an active site directed, reversible, tight binding and competitive inhibitor of PTPs 
(43). Together, these results underline the validity of our results. 
It is interesting to note that greater activity against one substrate or the other in the 
initial screen (Figure 2.7) often translated into differing potencies with the two substrates. 
For example, suramin appeared slightly more potent against the peptide 1 as a substrate 
than DiFMUP in the initial screen and has an IC50 that is 8-fold lower against the peptide 
in vitro. Conversely, sertraline (compound 4) appeared more potent against DiFMUP in 
the initial screen and has an IC50 that is 3.4-fold lower with DiFMUP. While the IC50 
values for these two compounds are less than 2-fold different against the substrate 
DiFMUP, they are 50-fold different against peptide 1. Most importantly, these in vitro 
differences in inhibitory potency seem to translate into differential biological activity. We 
tested the ability of suramin and sertraline to inhibit LYP activity in Jurkat T cells by 
monitoring the phosphorylation of LckY394, a known biological substrate of LYP. While 
suramin showed marked LYP inhibitory activity, manifested as an increase in 
phosphorylation at LckY394 (Figure 2.9), sertraline had no activity. It would appear that 
the ability of a compound to inhibit LYP-mediated hydrolysis of the more biologically 
relevant substrate, peptide 1, is a better predictor of biological activity than ability to 
inhibit LYP-mediated hydrolysis of a small molecule substrate. Inhibition of a peptide 
substrate has been used as a secondary screen to narrow down a panel of LYP inhibitors 











Figure 2.9. Suramin increases phosphorylation of Lck Y394 in human T cells. JTAg cells 
were preincubated with 25 µM compound (red graph) or DMSO alone (blue graphs) for 
30 min at 37°C followed by stimulation with C305 supernatent (solid graphs) or left 
unstimulated (dashed graphs) for 2 min at 37°C. Graphs show cell fluorescence after 
staining with an AlexaFluor-488-conjugated antiphospho-Lck(Y394) antibody. Median 
fluorescence intensity (MFI) of each sample is shown. The % positive cells in the 
compound-treated, TCR-stimulated sample compared to the DMSO-treated, TCR-





The most potent hit from our screen, epigallocatechin-3,5-digallate (EGCDG, 
compound 6), a pigment from green tea, is the most potent inhibitor of LYP and PTP-
PEST reported so far with IC50 of 50 nM against LYP and 20 nM against PTP-PEST. 
Notably, EGCDG is significantly less potent against CD45 (IC50 = 500 nM). In order to 
validate the biological relevance of this hit, we investigated the ability of EGCDG to 
inhibit LYP activity in T cells. In this case, we monitored the phosphorylation levels of 
Zap-70 Y319, a direct substrate of Lck and an extremely sensitive read-out of Lck 
activity. Gratifyingly, we found that treatment of Jurkat T cells with 500 nM EGCDG 
resulted in a significant increase in phosphorylation of Y319 in ZAP-70 as measured by 
phosphoflow cytometry (Figure 2.10), indicating inhibition of intracellular LYP activity 
resulting in an increase in intracellular Lck activity and restored T cell signaling. 
Molecular docking of EGCDG in LYP active site was performed to obtain a 
model for this binding and to gain further insight into this interaction (Figure 2.11). A 
binding score of -9.4 kcal/mol for EGCDG indicated high propensity of binding 
considering that the average docking score from 160 compounds selected randomly was -
4.7, and that the top 80 hits displayed an average docking score of -5.2 kcal/mol. The 
gallate moiety at 5-position of the EGCDG compound docked into the active site and was 
stabilized by cation-π interactions provided by R233 in the P-loop (residues 226-233), 
hydrogen bonding with K138 of the β3-β4 loop (residues 131-139) and T-shaped 
aromatic interaction with the Y60 residue of the pY recognition loop (residues 54-60). 
The gallate moiety at 5-position thus mimicked the key interactions observed in pY 
binding to the active site. This explains our experimental observation that the gallate 













Figure 2.10. Epigallocatechin-3,5-digallate increases activation of ZAP-70 in human T 
cells. JTAg cells were preincubated with 500 nM compound (red graphs) or DMSO alone 
(blue graphs) for 30 min at 37°C, followed by stimulation with C305 supernatant (solid 
graphs) or left unstimulated (dashed graphs) for 2 min at 37°C. Graphs show cell 
fluorescence after staining with an AlexaFluor-488-conjugated antiphospho-ZAP-70 
(Y319) antibody. Median fluorescence intensity (MFI) of each sample is shown. The % 
positive cells in the compound-treated, TCR-stimulated sample compared to the DMSO-
treated, TCR-stimulated sample was 22.8%. The % positive cells in the compound-





Figure 2.11. EGCDG docked pose. Most representative docked pose of 
Epigallocatechin-3,5-digallate from computer modeling. Left panel: LYP surface 
representation. Right panel: key residues interacting with the inhibitor.  
 
docked into the hydrophobic pocket adjacent to the WPD-loop (residues 193-204) 
adjacent to M130 and is stabilized by hydrogen bonding provided by backbone of K191. 
The pyrogallol-like ring of epigallocatechin preferentially interacted with WPD-loop, 
making hydrogen bonds with D195 and favorable Van der Waal interaction with W193, 
while the 7-hydroxy group of the epigallocatechin ring was found to make hydrogen 
bonds with T275 and E277 in the Q-loop (274-301). Interestingly, all the interactions 
involved in EGCDG docking were also observed in the MD simulations of the peptide 
substrate over the LYP surface (discussed in detail in Chapter 1). This observation further 
strengthens the rationale for using peptide 1 as a substrate in compound screening. 
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A closer investigation into the activity of compounds closely related to EGCDG 
supports some of the interactions found in the docking study, and provides insight into 
the structure-activity relationships of these compounds. EGCDG is a flavonoid belonging 
to the flavan-3-ol class. There were several closely related flavan-3-ols in our initial 
screen, as shown in Figure 2.12. With the exception of 2’,2’-bisepigallocatechin digallate, 
which showed some LYP inhibition (25% at 10 µM in the initial screen), several related 
epigallocatechins and catechins showed little to no inhibition of LYP activity (Table 2.5). 
In this series of compounds, EGCDG is the only compound with a gallate moiety at 5-
position of EGCDG. These data support the docking pose in which the 5-gallate moiety is 
involved in key interactions within the pY binding pocket. Gallic acid alone and other 
gallate esters did not inhibit LYP, indicating that the pY-mimicking ability of the 
polyphenols is not enough for potent inhibition of LYP. Furthermore, neither the 
interactions between LYP and the 3-gallate moiety nor the 7-hydroxy moiety are 
sufficient for potent inhibition, as evidenced by the fact that epigallocatechin-3-gallate 
had very little inhibitory activity. Finally, the presence of multiple gallate moieties is 
helpful but not sufficient for potent inhibition, as demonstrated by the moderate 
inhibitory potency of 2,2’-bisepigallocatechin digallate. Other closely related compounds 
from other classes of flavonoids such as, quercetin (3-hydroxyflavone) and naringenin 
(flavonone), did not inhibit LYP. However, several dihydroxyflavones and 
dihydroxyisoflavones showed varying degrees of LYP inhibition without a clear 
structure-activity relationship. Theaflavin, another polyphenolic compound from tea was 
found to inhibit LYP in the initial screening at 10 µM. However, it did not make a cut in 





















Figure 2.12. Structures and inhibition of LYP activity on peptide 1 at 10 µM of selected 








































































74 ± 15% inhibition
3',4'-dimethoxyflavone





0 ± 14% inhibition
Epicatechin


































93 ± 8% inhibition
5,7-dihydroxyisoflavone








Table 2.5. Inhibition of LYP activity on peptide 1 at 10 µM of selected compounds that 
are closely related to EGCDG structurally, other flavonoids and polyphenols from tea. 
COMPOUND NAME % ACTIVITY REMAINING ERROR 
EPIGALLOCATECHIN 3,5-DIGALLATE 7 8 
2',2'-BISEPIGALLOCATECHIN DIGALLATE 73 15 
EPIGALLOCATECHIN 77 28 
EPIGALLOCATECHIN-3-MONOGALLATE 96 19 
EPICATECHIN MONOGALLATE 104 14 
EPICATECHIN 114 17 
EPICATECHIN PENTAACETATE 101 5 
CATECHIN PENTAACETATE 110 1 
CATECHIN PENTABENZOATE 114 6 
CATECHIN TETRAMETHYLETHER 92 19 
GALLIC ACID 118 7 
4'-METHOXYFLAVONE 82 18 
5,7-DIMETHOXYISOFLAVONE 114 10 
3',6-DIHYDROXYFLAVONE 119 8 
3,4',5,6,7-PENTAMETHOXYFLAVONE 119 7 
6,4'-DIMETHOXYFLAVONE 75 18 
5-HYDROXY-2',4',7,8-TETRAMETHOXYFLAVONE 102 14 
7,8-DIHYDROXYFLAVONE 104 12 
3,5-DIHYDROXYFLAVONE 97 3 
6,4'-DIHYDROXYFLAVONE 92 6 
7,4'-DIHYDROXYFLAVONE 91 3 
3',4'-DIMETHOXYFLAVONE 22 6 
3,4'-DIHYDROXYFLAVONE 26 15 
7,2'-DIHYDROXYFLAVONE 116 20 
5,7-DIHYDROXYISOFLAVONE 28 49 
2-METHYL-5,7,8-TRIMETHOXYISOFLAVONE 86 60 
6,7-DIHYDROXYFLAVONE 115 9 
APIGENIN 97 5 
TANGERITIN 106 13 
CHRYSIN 105 15 
DIOSMIN 119 1 
QUERCETIN 103 2 
FISETINIDOL 98 11 
FISETIN 96 9 
HESPERETIN 103 7 
NARINGENIN 106 4 
THEAFLAVIN 25 13 
THEAFLAVIN MONOGALLATES 89 7 
THEAFLAVIN DIGALLATE 92 3 
EPITHEAFLAVIN MONOGALLATE 74 15 
TANNIC ACID 120 4 
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Gallate esters of theaflavin did not inhibit LYP. Another class of polyphenols from tea 
includes tannins and the representative compound of this group, tannic acid did not 




Here, we tested the hypothesis that the use of a more biologically relevant, 
peptide-based substrate in PTP inhibitor screens would result in hits with greater potential 
for biological activity. Our experimental screens for LYP inhibitors using both DiFMUP 
and peptide 1 as substrates demonstrated that, in some cases, different hits are identified 
with the two different substrates and, most importantly, that potency against the peptide 
substrate correlated more strongly with biological activity. Epigallocatechin-3,5-digallate 
(EGCDG) was identified as the most potent inhibitor of LYP to date, with an IC50 value 
of 50 nM and cellular activity at 500 nM. A first molecular model for the interaction of 
EGCDG with LYP was proposed based on molecular docking modeling, providing the 
basis for future lead optimization efforts. A first molecular model for the interaction of 
EGCDG with LYP was proposed based on molecular docking modeling, providing the 
basis for future lead optimization efforts. Interestingly, all the interactions observed in the 
binding of EGCDG were sampled by the peptide substrate in MD simulation, further 






2.4 Experimental section 
2.4.1 General considerations 
All of the reagents were purchased from commercial sources and used without 
further purification. The library of compounds, the Spectrum collection, was purchased 
from Microsource Discovery Systems, Inc. The pCAP residue and peptide 1 were 
synthesized as described previously by Mitra et al. (32). Stock solutions and serial 
dilutions of the substrates and inhibitors were made in DMSO. The catalytic domain of 
human recombinant CD45 was obtained from Biomol. The modified pBAD plasmid 
encoding the catalytic domain of HePTP (aa 44-339) in frame with a noncleavable 6xHis 
tag was obtained as a generous gift from Lutz Tautz. cDNA fragments encoding the 
catalytic domains of LYP (aa 2-309) and PTP-PEST (aa 2-323) were cloned between the 
BamH1 and the Xho1 sites of pET28a plasmid (Novagen) in frame with a cleavable N-
terminal 6xHis-tag. Recombinant proteins were purified from lysates of IPTG-induced 
Escherichia coli BL21 cells by affinity chromatography on Ni-nitrilotriacetic acid 
columns. 6xHisHePTP was eluted using 250 mM imidazole. Untagged LYP and PTP-
PEST were eluted by incubating columns with thrombin, followed by removal of 
thrombin from the protein preparation by a second chromatography step on benzamidine 
columns. All of the enzyme activity assays were performed at ambient temperature using 
a buffer containing 50 mM Tris, pH 6.5, 100 mM NaCl, 1 mM dithiothreitol (DTT), 2 
mM EDTA, and 0.01% Brij 35. Fluorescence data were collected on a Molecular Devices 
Spectramax M5 multimode plate reader with excitation and emission at 360 and 455 nm, 
respectively. The increase in the fluorescence due to the hydrolysis of the substrates was 
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measured every 60 s for 30 min and the fluorescence values in the linear range of the 
Michaelis-Menten kinetics curve were used for the data analysis. 
 
2.4.2 Library screening 
The Spectrum collection obtained consisted of 25 96-well plates, each of which 
contained 200 µM DMSO solutions of 80 compounds in columns 2-11.  A 5 µL aliquot 
of each of these compounds was transferred to corresponding position in the assay plate. 
A 5 µL aliquot of DMSO was transferred to each well of column 12 of the assay plate to 
serve as a control. A 1 µL aliquot of a DMSO solution of DiFMUP (150 µM stock) or 
peptide 1 (1 mM stock) was also transferred to the wells of the assay plates. The total 
amount of DMSO in each reaction well was held constant at 6% of the total reaction 
volume (100 µL). A 50 nM solution of enzyme in activity buffer was preincubated with 1 
mM DTT for 30 min to ensure complete activation. The preactivated enzyme was further 
diluted with the activity buffer just prior to addition to the assay plate, so that addition of 
a 94 µL of the diluted enzyme to each well would result in a final enzyme concentration 
of 5 nM. The final DTT concentration in each reaction well was 100 µM. The final 
concentrations of the substrates used were 1.5 µM and 10 µM for DiFMUP and peptide 
1, respectively. The final concentration for each compound screened in the library was 10 
µM. Upon addition of the preactivated enzyme, the enzyme activity was monitored at 
room temperature (21-24˚C) in black 96-well plates. The activity of the enzyme was 
measured by monitoring the increase in fluorescence (lex = 360 nm, lem = 455 nm) every 
60 s for 30 min as the enzyme dephosphorylated the substrate (either DiFMUP or peptide 
1). Each source plate in the library was screened in triplicate with each of the substrates 
 69 
and results were averaged. The percent relative activity for each compound was 
determined by factoring the measured fluorescence values for the compound treated wells 
over the control wells treated with DMSO only.  
 
2.4.3 Inhibition assays 
 Stock solutions and serial dilutions of the compounds for determination of IC50 
were made in DMSO. All the hits were screened at inhibitor concentrations ranging 
between 100 nM to 500 µM.  The total DMSO concentration in each reaction was held 
constant at 6% of the total reaction volume (100 µL). The concentrations of enzymes, 
DTT and substrates were the same as those used in the library screening assays. The 
percent relative activity at different concentrations was determined by factoring the 
measured fluorescence values for the compound treated wells over the control wells 
treated with DMSO only. The resulting plot of inhibitor concentration versus percent 
enzyme activity provided the IC50 values. 
 
2.4.4 Cell culture  
Jurkat T cells expressing the SV-40 large T Antigen (JTAg) (48) were kept at 
logarithmic growth in RPMI 1640 medium (Mediatech, Manassas, VA) supplemented 
with 10% fetal bovine serum (Omega Scientific, Tarzana, CA), 2 mM glutamine, 1 mM 
sodium pyruvate, 10 mM HEPES pH 7.3, 2.5 mg/ml D-glucose, 100 units/ml of penicillin 




2.4.5 Phospho-flow cytometry  
JTAg cells were pretreated with the indicated concentrations of LYP inhibitors or 
DMSO for 30 min in RPMI 1640 at 37°C. Cells were then stimulated with supernatants 
of C305 hybridoma (49) for 2 min at 37°C. Cells were fixed immediately with BD 
Cytofix buffer, permeabilized using BD Phosflow Perm Buffer III and stained with 
AlexaFluor-488-conjugated anti-pZAP-70(Y319) antibody or anti-pSrc(Y418) antibody 
(which is cross-reactive with pLck(Y394), and labeled as such in Figure 2.9) according to 
the manufacturer’s protocols (BD Biosciences, San Jose, CA). Cell fluorescence was 
analyzed by FACS using a BD LSR II (BD Biosciences). Data was analyzed using 
FlowJo software (TreeStar, Ashland, OR). 
 
2.4.6 Docking Simulations  
The Schrödinger suite of programs (50) was used for the docking studies. The 
crystal structure (PDB entry 2P6X) prepared for the simulation was utilized for docking 
the library of compounds. A scoring grid was precomputed by placing an outer cubical 
box of length 36 Å and an inner box of length 14 Å centered at the P-loop residues (227-
231). The hydroxyl groups of all Ser, Thr, and Tyr residues in the binding site were 
allowed to be flexible during the grid generation process. Docking calculations were 
performed using Glide (version 5.7) (51). The ligand library comprised of hit compounds 
from the experimental screening and were prepared using LigPrep (50). Low energy 
conformations were generated for all possible protonation and ionization states (pH range 
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The improper regulation of tyrosine phosphorylation levels is implicated in 
multiple human diseases including diabetes, cancer, hypertension and autoimmunity (1). 
As a consequence, there is significant interest in identifying chemical inhibitors of the 
enzymes responsible for regulating tyrosine phosphorylation, namely the tyrosine kinases 
and protein tyrosine phosphatases (PTPs). One enzyme of particular interest in 
autoimmunity is the lymphoid tyrosine phosphatase (LYP, PTPN22), a negative regulator 
of early T cell receptor (TCR) signaling (2). An allelic gain of function variant of LYP is 
associated with various autoimmune disorders (3, 4), whereas an allelic loss of function 
variant is protective against systemic lupus erythematosus (5). LYP is also found to be a 
positive regulator of anaphylaxis and inhibition of LYP helps to mitigate anaphylaxis in 
mice (6). Taken together, these findings reinforce the potential of LYP inhibition for the 
treatment of autoimmune disorders.  
The catalytic domains of PTPs are homologous and all contain the PTP signature 
motif, (H/V)C(X)5R(S/T), in the conserved PTP active site (7). The local environment in 
the PTP active site lowers the pKa of the active site cysteine residue making it highly 
nucleophilic and susceptible to oxidation (8). Therefore, several PTPs including LYP are 
inactivated and regulated by reversible or irreversible oxidation of the activated catalytic 
cysteine residue upon exposure to oxidizing agents such as H2O2 and NO (8-11). The 
Barrios laboratory has previously shown that nitrosating agents such as sodium 
nitroprusside and the active site-directed nitric oxide (NO)-donating peptide, Ac-
ARLIEDNE-(HCyNO)-TAREG-NH2, also cause reversible, competitive and covalent 
oxidative inactivation of LYP (12). Thiophilic heavy metals including zinc(II), gold(I) 
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and mercury(II) readily inhibit activities of several PTPs including LYP (13-16). In 
addition, S-thiolation can inhibit PTP activity. For example, PTP1B is inhibited by 
hydrogen sulfide-mediated S-thiolation during ischemia and reperfusion (17). 
Furthermore, in the presence of excess of H2O2 in vitro, the catalytic cysteine residue of 
LYP forms a disulfide bond with the backdoor C129 to reversibly inactivate the enzyme 
(18). These examples illustrate the diverse mechanisms by which PTP activity can be 
regulated by virtue of the reactivity of the catalytic cysteine residue.  
In Chapter 1 of this dissertation, I have discussed in detail how potent and 
selective inhibitors of LYP can be developed by mimicking the mechanisms of biological 
regulation of LYP. We have also discussed advantages of chemical probes that can form 
covalent bond with LYP for addressing biological problems pertaining to LYP. Towards 
this end, we decided to exploit oxidation of the catalytic cysteine residue for inhibition of 
LYP. With this in mind, we looked for classes of compounds that can covalently modify 
low pKa thiols by oxidation.  
Thiuram disulfides are a chemically distinct class of disulfides that can inhibit 
enzymes containing low pKa thiols by forming mixed disulfides (19). A prototype of this 
class of compounds, disulfiram (Figure 3.1, trade name Antabuse), is used clinically for 
the treatment of alcohol dependence (20). Disulfiram inhibits aldehyde dehydrogenase, 
an enzyme involved in alcohol metabolism, leading to acetaldehyde build-up and 
unpleasant symptoms following the ingestion of alcohol (21). Inhibition of aldehyde 
dehydrogenase by disulfiram is irreversible and recovery of the activity of aldehyde 
dehydrogenase is dependent on synthesis of new enzyme in vivo (22). The mechanism of 










Figure 3.1. Mixed disulfide bond formation between disulfiram and proteins containing 
low pKa thiols. 
 
disulfide bond between disulfiram and a catalytically essential cysteine residue of the 
enzyme as shown in Figure 3.1 (21, 23, 24). The product of this reaction, 
diethyldithiocarbamate, is a metabolite of disulfiram and is capable of inhibiting aldehyde 
dehydrogenase in vivo but not in vitro (22, 25, 26). This observation has been attributed 
to oxidation of diethyldithiocarbamate to disulfiram in vivo (27). Disulfiram along with 
another thiuram disulfide, thiram and several dithiocarbamates have also been shown to 
possess anticancer activity (28-31). This potent anticancer activity of disulfiram has been 
attributed to S-thiolation of several biological targets including protein kinase C (PKC) 
(19), glutathione-S-transferase (GST) (32), nuclear factor-κB (33) and the caspases (34) 
along with other mechanisms. Based on the known biological activity of disulfiram and 
the knowledge that LYP is inactivated by oxidation and disulfide bond formation, we 













3.2 Results and discussion 
To test this hypothesis, we first investigated the inhibition of LYP and other 
closely related PTPs by disulfiram. Disulfiram inhibited LYP activity with a moderate 
potency (IC50 = 47 ± 2 µM) but surprisingly did not inhibit the activity of PTP-PEST or 
CD45 at 500 µM. Disulfiram was then tested for in-cell LYP inhibition in the Jurkat T 
Antigen (JTAg) cells. LYP negatively regulates early stage T cell receptor (TCR) 
signaling by dephosphorylating Lck at position Y394 (35). Therefore, by following the 
phosphorylation at Lck Y394, activity of the cellular LYP can be monitored. Figure 3.2 
shows that the treatment of JTAg cells with increasing concentrations of disulfiram 
resulted in dose-dependent increase in phosphorylation of LCK Y394 as observed with 
anti-pSrc(Y416) immunoblot that cross-reacts with pLCK(Y394) and phospho-flow 
cytometry. CD45 is another PTP found in T cells. It dephosphorylates pLCK(Y505) and 
this results in turning on of the TCR signaling (4). Therefore, inhibition of CD45 activity 
would counteract any benefit obtained from inhibition of LYP. To test whether disulfiram 
inhibited CD45 activity in JTAg cells we monitored levels of phosphorylation on Lck 
Y505. Diethyldithiocarbamate is the reduction product and metabolite of disulfiram and it 
inhibits aldehyde dehydrogenase in vivo but not in vitro. To test the effects of this 
compound, we decided to study its LYP and CD45 inhibition in JTAg cells. The results 
of this in-cell LYP and CD45 inhibition study for cells incubated in the presence and 
absence of either disulfiram or diethyldithiocarbamate, with and without TCR stimulation 
are shown in Figure 3.3. The TCR stimulated cells (lanes 2 and 4) show an increase in 
phosphorylation at Y394 in the presence of disulfiram as observed also in Figure 3.2 but 















Figure 3.2. Intracellular dose-dependent inhibition of LYP by disulfiram. (A) JTAg cells 
were treated for 30 min with DMSO (lanes 1 and 2) or increasing concentrations of 
disulfiram (lanes 3-5), and stimulated for 2 min using C305 supernatant (lanes 2-5) or left 
unstimulated (lane 1). Upper panel shows anti-pSrc(Y416) immunoblot. Lower panel 
shows anti-Lck blot of the same samples. (B-F) Single-cell analysis of TCR-induced 
phosphorylation of Lck by phospho-flow cytometry. JTAg cells were treated for 30 min 
with DMSO (B and C) or increasing concentrations of disulfiram (D-F), and stimulated 
for 2 min using C305 supernatant (C-F) or left unstimulated (B). Cells were fixed and 
stained with an AlexaFluor-488-conjugated anti-pSrc(Y416) antibody. Graphs show 
relative pLck(Y394) levels of live cells gated by FSC versus SSC. Red gate within each 
panel includes cells with phospho-Lck expression equal to or higher than the top 5% of 















Figure 3.3. Intracellular inhibition of LYP by disulfiram and dietthyldithiocarbamate. 
Top panels: anti-pSrc(Y416) immunoblots of lysates of Jurkat TAg cells treated with 75 
µM of Disulfiram and Imuthiol (lanes 3 and 4 in each panel) or untreated (lanes 1 and 2 
in each panel) and either left unstimulated (lanes 1 and 3 in each panel) or stimulated 
(lanes 2 and 4 in each panel) with C305 antibodies for 2 min. Middle panels: anti-









not inhibit LYP activity in JTAg cells. Phosphorylation levels at position Y505 of Lck in 
the presence of either disulfiram or diethyldithiocarbamate are unaltered indicating that 
these compounds do not inhibit CD45 activity in cells. These results are consistent with 
the in vitro screening results, confirming that disulfiram inhibits LYP selectively over 
CD45 in cells. 
Since disulfiram showed excellent dose-dependent inhibition of LYP in cells with 
a moderate potency, we decided to look for other thiuram disulfide inhibitors with greater 
potency. With this in mind, we screened a library of 16 commercially available thiuram 
disulfides (Figure 3.4) for inhibition of LYP. In our screen, we included the sodium salt 
of diethyldithiocarbamate (compound 17), which was expected to be a negative control 
based on our observation that it did not inhibit LYP in JTAg cells. We also included 
disulfiram (compound 1) and epigallocatechin-3,5-digallate (EGCDG) (compound 18), 
the most potent inhibitor of LYP and PTP-PEST reported so far as positive controls (16). 
Each compound in the library was screened in triplicate at 10 µM and 50 µM 
concentrations, except the positive control, EGCDG, which was screened at 100 nM and 
500 nM concentrations. The results of this screening exercise are summarized in Figure 
3.5. Compounds that showed more potent inhibition of LYP than disulfiram in the initial 
screening were carried forward for further validation and counter-screening against PTP-
PEST. The IC50 values of these hits are summarized in Table 3.1.  
Tetraethylthiuram disulfide (disulfiram, compound 1) was found to be a better 
inhibitor of LYP than tetramethyl (thiram, compound 2) and tetrabutyl (compound 4) 
analogs. However, increasing the steric bulk around the thiuram nitrogens with 











































Figure 3.4. Structures of the compounds screened as LYP inhibitors. 
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Figure 3.5. Results of initial screen to identify LYP inhibitors. (A) Compounds 1-17 
were screened at 10 µM concentration, while epigallocatechin-3,5-digallate (compound 
18) was screened at 100 nM, (B) compounds 1-17 were screened at 50 µM concentration, 







































Table 3.1. Hit validation and counter screening of selected hits against PTP-PEST. IC50 
values are shown in µM. 
Compound # LYP  PTP-PEST  
1 47 ± 2 > 500 
3 7.0 ± 0.7 20 ± 1 
10 15.0 ± 0.5 25 ± 2 
11 23 ± 3 70 ± 5 
12 10 ± 1 10 ± 2 
13 3.0 ± 0.3 8.0 ± 0.5 
15 13 ± 1 38 ± 5 
16 34 ± 3 44 ± 6 
 
Replacing one or both alkyl substituents of each thiuram nitrogen with an aryl substituent 
is generally not well tolerated, with compounds 5, 6, 8 and 9 showing no or very low 
inhibition of LYP. However, among the aromatic substituted compounds, compound 7, 
containing a strongly electron withdrawing aryl ring showed the best activity against 
LYP. Cyclizing the substituents on the thiuram nitrogens to form a piperidine (compound 
10) or morpholine (compound 11) ring leads to more potent inhibition, providing 
additional evidence that increasing steric bulk around the thiuram nitrogens increases 
potency of LYP inhibition. Monosubstitution of the thiuram nitrogens is also well 
tolerated with compounds 12, 13 and 15 showing potent inhibition of LYP. However, 
monosubstitution with an electron withdrawing aryl ring is not nearly as well tolerated 
(with compound 14 showing only moderate inhibition of LYP). Monosubstitution with a 
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sulfolane moiety (compound 15) provided greater inhibition of LYP than disubstitution 
with one sulfolane moiety and a methyl group (compound 16). The most potent thiuram 
disulfide inhibitor was compound 13, in which both of the thiuram nitrogen atoms are 
monosubstituted with N-(2-thioxothiazolidin-4-one). In a counter-screen, all of the hits 
excluding compound 10 showed more potent inhibition of LYP than the highly similar 
PTP-PEST but none of these hits showed as much preference of LYP over PTP-PEST as 
the prototype, disulfiram (compound 1).  
Disulfiram is known to inhibit several of its targets by forming mixed disulfides 
with low pKa cysteine residues and this covalent inhibition can usually be reversed by 
adding thiol reducing agents such as DTT or 2-mercaptoethanol (19, 24, 32). To 
determine whether our top hit, compound 13, is a pseudo-irreversible inhibitor of LYP 
activity, we investigated characteristic features of covalent inhibition. With this in mind, 
we first tested whether washing away the inhibitor could reverse LYP inhibition of 
compound 13. For this, preactivated LYP was incubated with compound 13 to ensure 
inhibition and then subjected to prolonged dialysis with 3 exchanges of the dialysis buffer 
to give a total of 109-fold dilution (Figure 3.6). Only a little activity was lost even after 
prolonged dialysis, in the DMSO-treated control LYP while the activity of the compound 
13-treated LYP could not be restored, indicating that the inhibitor cannot be washed away 
from the enzyme. When activity of LYP was monitored upon incubation with several 
concentrations of compound 13, compound 13 showed time-dependent and 
concentration-dependent inhibition (Figure 3.7A), indicating initial binding and formation 
of covalent bond. A plot of observed rate constants for the product formation versus the 


















Figure 3.6. Inhibition of LYP by compound 13 cannot be reversed by dialysis. Twenty 
five µM LYP was incubated with 500 µM of compound 13 for 90 min and then dialyzed 
for 3 exchanges each of 1000-fold dialysis buffer to get a final 109-fold dilution. The 
activities of LYP are normalized to those obtained from DMSO-treated control sample at 
t=0. The black bar represents the activity of the compound 13 treated sample, while the 
















































Figure 3.7. Compound 13 inhibits LYP in a time-dependent manner. (A) Activity of 2 
nM LYP treated with various concentrations of compound 13 was measured at 30 s 
intervals and the observed rate constant (kobs) for each reaction was calculated as 
described in the experimental section. (B) A plot of kobs versus [compound 13] gave Kapp 
and Kinact as described in the experimental section. 
Ki = 1.1 ± 0.4 µM 







































covalent inhibitors. Compound 13 was found to inhibit LYP with Ki of 1.1 ± 0.4 µM and 
kinact of 0.0040 ± 0.0007 s-1.  
If the covalent bond between compound 13 and LYP is indeed a disulfide bond, 
this disulfide bond can at least be partially reversed by addition of thiol reducing agents. 
To test this, we incubated LYP with compound 13 to ensure inhibition and then incubated 
this inhibited LYP with several high concentrations of either DTT or glutathione. 
Inhibition of LYP by compound 13 was partially reversed in a dose-dependent manner by 
postincubation with DTT (Figure 3.8A) but could not be reversed significantly by 
glutathione, the physiological reducing agent (Figure 3.8B). Lack of 100% recovery of 
the LYP activity was not entirely surprising as reactivation kinetics for thiols is estimated 
to be 10-1000 times slower than inactivation by oxidation (36, 37). Together with the 
finding that inhibition of LYP by compound 13 is time-dependent and cannot be reversed 
by dialysis, we can conclude that compound 13 inhibits LYP covalently by S-thiolation, 
and although this inhibition can be partially reversed by DTT, it is likely to be 
irreversible under physiological conditions. When LYP was coincubated with compound 
13 and reducing agent, either DTT (Figure 3.9A) or glutathione (Figure 3.9B), the ability 
of compound 13 to inhibit LYP was diminished significantly, indicating that the 
corresponding dithiocarbamate formed may have much lower LYP inhibitory potency in 
vitro.  
To confirm this, we preincubated compound 13 with the reducing agents for 1 h 
to ensure reduction of compound 13 to the corresponding dithiocarbamate and we found 



























Figure 3.8. Inhibition of LYP by compound 13 can be partially reversed by posttreatment 
with DTT (A) but not by glutathione (B). Five nM LYP was incubated with 5 µM of 
compound 13 for 30 min followed by postincubation with various concentrations of (A) 
DTT or (B) glutathione for 1 h. The activities of LYP are normalized to those obtained 
from DMSO-treated control sample that are not treated with DTT. The black bar 
represents the activity of the compound 13 treated sample, while the activity of an 








































































Figure 3.9. Ability of compound 13 to inhibit LYP diminishes significantly by co-
incubation with DTT (A) and partially by coincubation with glutathione (B). Five nM 
LYP was coincubated simultaneously with 5 µM of compound 13 and various 
concentrations of DTT (A) or glutathione (B) for 1 h. The activities of LYP are 
normalized to those obtained from DMSO-treated control sample that are not treated with 
DTT. The black bar represents the activity of the compound 13 treated sample, while the 












































































Figure 3.10. Ability of compound 13 to inhibit LYP diminishes significantly by pre-
incubation with DTT (A) and partially by preincubation with glutathione (B). Five nM 
LYP was incubated for 30 min with 5 µM of compound 13 that was preincubated with 
various concentrations of DTT for 1 h. The activities of LYP are normalized to those 












































with our earlier finding that diethyldithiocarbamate (compound 17), a reduced form of 
disulfiram, did not inhibit LYP in vitro and in cells at the concentrations tested. Both 
these findings reinforce our hypothesis that the thiol-disulfide exchange is essential for 
potent LYP inhibition as the monosulfides showed weak inhibition. 
With the aim of validating the biological relevance of our best hit, we then tested 
compound 13 for in-cell LYP inhibition in the JTAg cells. As mentioned earlier, LYP 
negatively regulates early stage T cell receptor (TCR) signaling by dephosphorylating 
Lck at position Y394 (38). Phosphorylation of Lck at Y394 activates the kinase which, in 
turn, phosphorylates ZAP-70 Y319. Therefore, by monitoring the phosphorylation levels 
of Y319 of ZAP-70, we obtain a sensitive read-out for LYP activity in JTAg cells (16). 
Upon treatment of JTAg cells with compound 13, phosphorylation levels of ZAP-70 
Y319 increased in a dose-dependent manner in both unstimulated and stimulated cells, as 
measured by phospho-flow cytometry. These results indicate that compound 13 inhibits 
LYP activity in JTAg cells, promoting T cell activation (Figure 3.11). 
In order to gain further insights into the structure activity relationship for LYP 
inhibition by the thiuram disulfides, Dr. Nadeem Vellore from Dr. Riccardo Baron’s 
laboratory performed an atom-based 3D Quantitative-Structure-Activity-Relationship 
(QSAR) study (39, 40). By iteratively using 12 out of the 17 (70%) compounds as the 
training set, 3D QSAR model was generated to predict the remaining activity for the 30% 
of the compounds in the test set. Figure 3.12 displays the correlation between predicted 
versus experimental remaining activity (R2 value of 0.8). The individual contribution of 












Figure 3.11. The LYP inhibitor compound 13 increases T cell activation. Compound 13 
increases activation of ZAP-70 in human T cells. JTAg cells were preincubated with 25 
µM (green graphs), 50 µM (purple graphs), or 100 µM (red graphs) compound 13 or with 
DMSO alone (blue graphs) for 30 min at 37°C, followed by stimulation with C305 
supernatant (solid graphs) or left unstimulated (dashed graphs) for 2 min at 37°C. Graphs 
show cell fluorescence after staining with an AlexaFluor-488-conjugated antiphospho-
ZAP-70 (Y319) antibody. Median fluorescence intensity (MFI) of each sample is shown. 
The % of positive cells was calculated for each sample by Overton subtraction (41). The 
% positive cells for the compound-treated TCR-stimulated samples compared to the 
DMSO-treated TCR-stimulated samples were 12.5%, 20.1%, and 26.0% for 25 µM, 50 
µM, and 100 µM compound 13, respectively. The % positive cells for the compound-
treated unstimulated samples compared to the DMSO-treated unstimulated samples were 










Figure 3.12. Atom-based QSAR study. (A) Aligned compounds with blue shading over 
the hydrophobic or nonpolar region of the compounds, highlighting the features that 
positively correlated with the experimental activity, (B) QSAR model scatter plot with 
experimental versus predicted activity remaining based atom-based 3D-QSAR 
approaches (values are in %). 
 
Table 3.2. Percentage atomic property associated in predicting the activity based on 





H-bond donor 0.16 
Hydrophobic or nonpolar 63.61 
Negative ionic 3.37 





indicate the physicochemical properties of the ligands contributing to the predicted 
QSAR. Overall, the presence of hydrophobic/nonpolar moieties and electron withdrawing 
groups on the thiuram nitrogen were the most important factors contributing to low 
micromolar LYP inhibition, accounting for a total of 77% of the overall  
contribution.  
Disulfiram is known to inhibit several of its targets by forming mixed disulfides 
with low pKa cysteine residues and its covalent inhibition can often be reversed by adding 
thiol reducing agents such as DTT or 2-mercaptoethanol (19, 24, 32). We suggest the 
following mechanistic interpretation based on the integration of our experimental and 
computational data. Substitution of thiuram nitrogen with electron withdrawing groups 
might aid in activating the nucleophilic attack by the catalytic cysteine residue of LYP 
onto the thiuram disulfide; whereas substitution with hydrophobic groups might provide 
favorable Van der Waals interactions with the active site of LYP. 
 
3.3 Conclusions 
In the present study, we have screened a library of thiuram disulfides against LYP 
to identify several low micromolar, covalent, pseudo-irreversible LYP inhibitors. 
Disulfiram inhibited LYP preferentially over CD45 both in vitro and in Jurkat T-cells. 
However, the reduced metabolite of disulfiram, diethyldithiocarbamate, did not inhibit 
LYP activity in vitro or in cells, indicating the importance of thiol-disulfide exchange 
reaction for the potency of thiuram disulfides. Computational modeling and Quantative-
Structure-Activity-Relationship indicates that the presence of hydrophobic/nonpolar 
moiety and electron-withdrawing groups on the thiuram nitrogen were the most important 
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factors contributing to the LYP inhibition. Compound 13, an N-(2-thioxothiazolidin-4-
one) analog, was the most potent LYP inhibitor in this library with IC50 of 3 µM and Ki 
of 1.1 µM. Compound 13 showed covalent inhibition of LYP that cannot be reversed by 
dialysis but can be partially reversed by treatment with DTT. The reduced product of 
compound 13, the corresponding dithiocarbamate, only weakly inhibited LYP. 
Compound 13 was further shown to inhibit LYP in Jurkat T-cells in a dose-dependent 
manner to activate T-cell signaling. 
 
3.4 Experimental section 
3.4.1 General considerations 
All the reagents were purchased from commercial sources and used without 
further purification. The library of thiuram disulfides was purchased from Aldrich Market 
Select. Stock solutions and serial dilutions of the substrates were made in DMSO. cDNA 
fragments encoding the catalytic domains of LYP (aa 2-309) and PTP-PEST (aa 2-323) 
were cloned between the BamH1 and the Xho1 sites of pET28a plasmid (Novagen) in 
frame with a cleavable N-terminal 6xHis-tag. Recombinant proteins were purified from 
lysates of IPTG-induced Escherichia coli BL21 cells by affinity chromatography on Ni-
nitrilotriacetic acid columns. 6xHisHePTP was eluted using 250 mM imidazole. 
Untagged LYP and PTP-PEST were eluted by incubating columns with thrombin, 
followed by removal of thrombin from the protein preparation by a second 
chromatography step on benzamidine columns. The catalytic domain of human 
recombinant CD45 was obtained from Enzo life sciences. All of the activity assays with 
all of the enzymes were performed at ambient temperature using a buffer containing 50 
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mM Bis-Tris, pH 6.5, 100 mM NaCl, 1 mM Tris (2-carboxyethyl)phosphine 
hydrochloride (TCEP), 2 mM EDTA, and 0.01% Brij 35. Fluorescence data were 
collected on a Molecular Devices Spectramax M5 multimode plate reader with excitation 
and emission at 360 and 455 nm, respectively. The increase in the fluorescence due to the 
hydrolysis of the substrates was measured every 60 s for 30 min and the fluorescence 
values in the linear range of the Michaelis-Menten kinetics curve were used for the data 
analysis. 
 
3.4.2 In vitro assay for library screening 
The library of thiuram disulfides was created in a source plate with 1 mM DMSO 
solution of compounds 1-17 and 10 µM DMSO solution of the compound 18 
(epigallocatechin-3,5-digallate). A 5 µL aliquot or a 1 µL aliquot of each of these 
compounds was transferred to corresponding position in the assay plate for screening at 
inhibitor concentration of 50 µM or10 µM, respectively. A 4 µL aliquot of DMSO was 
transferred to each well containing inhibitor of the assay plate when screening at 10 µM 
inhibitor concentration but not when screening at 50 µM inhibitor concentration. A 5 µL 
aliquot of DMSO was transferred to each of the control wells. A 1 µL aliquot of a DMSO 
solution of DiFMUP (150 µM stock) was also transferred to the wells of the assay plates. 
The total amount of DMSO in each reaction well was held constant at 6% of the total 
reaction volume (100 µL). A 50 nM solution of enzyme in activity buffer was 
preincubated with 1 mM TCEP for 30 min to ensure complete activation. The 
preactivated enzyme was further diluted with the activity buffer just prior to addition to 
the assay plate, so that addition of a 94 µL of the diluted enzyme to each well would 
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result in a final enzyme concentration of 5 nM. The final TCEP concentration in each 
reaction well was 100 µM. The final concentration of DiFMUP was 1.5 µM. Each 
compound in the library was screened in triplicate and results were averaged. The percent 
relative activity for each compound was determined by factoring the measured 
fluorescence values for the compound treated wells over the control wells treated with 
DMSO only.  
 
3.4.3 In vitro inhibition assays 
Stock solutions and serial dilutions of the compounds for determination of IC50 
were made in DMSO. All the hits were screened at inhibitor concentrations ranging 
between 500 nM to 500 µM.  The total DMSO concentration in each reaction was held 
constant at 6% of the total reaction volume (100 µL). The concentrations of enzymes 
(both LYP and PTP-PEST), TCEP and substrates were the same as those used in the 
library screening assays. The percent relative activity at different concentrations was 
determined by factoring the measured fluorescence values for the compound treated wells 
over the control wells treated with DMSO only. The resulting plot of inhibitor 
concentration versus percent enzyme activity provided the IC50 values. 
For determination of the dissociation constant, Ki, the final concentration of LYP 
used was 2 nM and the concentration of DiFMUP used was 5 µM. The remaining 
conditions were the same as those used in the library screening assay. The increase in the 
fluorescence due to the hydrolysis of the substrates was measured in 30 s intervals for 30 
min and the fluorescence values in the linear range of the Michaelis-Menten kinetics 
curve were used for the data analysis. The dissociation constant (Ki) and the first order 
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rate constant for covalent bond formation (kinact) were calculated as described by Gushwa 
et al. (42). In short, for each inhibitor concentration, an observed rate constant (kobs) was 
calculated using the equation P = (vi/kobs)(1-e(-kobst)), where P = product formation, vi = 
initial velocity, and t = time. The apparent dissociation constant (Kapp) for the reversible 
enzyme inhibitor complex and the first order rate constant for covalent bond formation 
(kinact) were obtained by a nonlinear regression analysis of the derived kobs values at 
different inhibitor concentrations with equation kobs = kinact[I]/(Kapp+[I]). The dissociation 
constant (Ki) was calculated using the formula Ki = (Kapp/(1+[DiFMUP]/KmDiFMUP) where 
KmDiFMUP = Km of DiFMUP was determined experimentally.  
 
3.4.4 Reversibility by dialysis 
Twenty-five µM LYP was preincubated with 1 mM TCEP for 1 h to ensure 
complete activation. After this, 500 µM compound 13 or DMSO control was added to the 
enzyme and aliquots of these reactions were used to determine the activity of LYP at t=0 
and after 90 min incubation using the conditions similar to those used in library screening 
assay. The reaction mixture was then dialyzed using Pierce Slide-a-Lyzer MINI 20k 
dialysis tubes against the activity buffer described in the general considerations for three 
exchanges of prolonged dialysis at 4°C to achieve 109-fold dilution. LYP activity was 
determined postdialysis and was normalized using the activity obtained with the DMSO 





3.4.5 Reversibility with reducing agents  
Five nM LYP was preincubated with 1 mM TCEP for 1 h to ensure complete 
activation. For postincubation with reducing agent studies, we then incubated the 
activated LYP with either 5 µM compound 13 or DMSO for 30 min. After 30 min, 
different concentrations of DTT or glutathione were added to the reactions and incubated 
for 1 h and the LYP activity was measured as described in library screening assays, 
except that the concentration of DiFMUP used was 5 µM. For coincubation studies, 
activated LYP was incubated simultaneously with different concentrations of DTT or 
glutathione and 5 µM compound 13 for 1 h, following which the LYP activity was 
measured as described above. For preincubation studies, 5 µM compound 13 was 
preincubated with different concentrations of DTT or glutathione for 1 h and then this 
preincubated mixture was added to the preactivated LYP and incubated 30 min further, 
following which the LYP activity was measured as described above. For all these 
reactions, the LYP activity remaining was normalized using the activity obtained with the 
DMSO control treated LYP that was not treated with DTT or glutathione.  
 
3.4.6 Antibodies 
The polyclonal anti-pSrc(Tyr416) (cross-reactive with pLck(Tyr394)) and anti-
pTyr505-Lck and antibodies were obtained from Cell Signaling Technology, Inc. The 
monoclonal anti-Lck antibody was obtained from Santa Cruz Biotechnology. The ECL-




3.4.7 Cell culture 
Jurkat T cells expressing the SV-40 large T Antigen (JTAg) (43) were kept at 
logarithmic growth in RPMI 1640 medium (Mediatech, Manassas, VA) supplemented 
with 10% fetal bovine serum (Omega Scientific, Tarzana, CA), 2 mM glutamine, 1 mM 
sodium pyruvate, 10 mM HEPES pH 7.3, 2.5 mg/ml D-glucose, 100 units/ml of penicillin 
and 100 µg/ml streptomycin (Life Technologies, Carlsbad, CA).  
 
3.4.8 Studies with JTAg Cells 
Fixed concentrations of inhibitors or DMSO (control) were added to 20 X 106 
cells suspended in 800 µL RPMI 1640, and incubated for 1 h at room temperature. The 
volume of DMSO added was held constant at less than 2% of the total volume. JTAg 
cells preincubated with DMSO or inhibitor were divided into 400 µL aliquots containing 
10 X 106 cells and stimulated with supernatants of C305 hybridoma (44) for 2 min or left 
untreated. Cells were lysed in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA pH 
8.0 containing 1% NP-40, 10 µg/mL aprotinin and leupeptin, 10 µg/mL soybean trypsin 
inhibitor, 1 mM Na3VO4, and 1 mM phenylmethylsulfonyl fluoride, after which lysates 
were clarified by centrifugation. The protein concentration in each cell lysate was 
determined by Bradford protein assay (Bio-Rad) in order to normalize the amount of 
protein used in SDS-PAGE. 
 
3.4.9 SDS-PAGE and immunoblots  
Aliquots of lysates were suspended in SDS sample buffer, heated at 95 °C for 5 
min and the boiled samples run on 10% (single concentration) or 8% (dose-response) 
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SDS-polyacrylamide gels. Proteins resolved by gel electrophoresis were transferred onto 
nitrocellulose membranes (Hybond ECL, GE Healthcare), using appropriate dilutions per 
manufacturer’s instructions of unconjugated primary antibodies followed by horseradish 
peroxidase-conjugated secondary antibodies (purchased from GE Healthcare). Blots were 
developed with the enhanced chemiluminescence detection system, ECL-Plus, following 
manufacturer’s directions. 
 
3.4.10 Phospho-flow cytometry 
JTAg cells were pretreated with the indicated concentrations of LYP inhibitors or 
DMSO for 30 min in RPMI 1640 at 37°C. Cells were then stimulated with supernatants 
of C305 hybridoma (44) for 2 min at 37°C. Cells were fixed immediately with BD 
Cytofix buffer, permeabilized using BD Phosflow Perm Buffer III and stained with 
AlexaFluor-488-conjugated anti-pZAP-70(Y319) antibody or anti-pSrc(Y416) antibody 
(which is cross-reactive with pLck(Y394), according to the manufacturer’s protocols (BD 
Biosciences, San Jose, CA). Cell fluorescence was analyzed by FACS using a BD LSR II 
(BD Biosciences). Data was analyzed using FlowJo software (TreeStar, Ashland, OR). 
 
3.4.11 3D QSAR modeling 
Quantitative structure activity relationship (QSAR) studies were performed on the 
selected 17 compounds (39, 40). Relative percentage activity remaining upon treatment 
with 50 µM inhibitor was used as the desired experimental activity, as IC50s were not 
available for all the compounds and the activity remaining upon treatment with 50 µM 
inhibitor correlated well with the IC50s of the most of the compounds. Three-dimensional 
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conformations of the all the compounds were generated using LigPrep module of 
Schrödinger program (45). Only the lowest energy conformations were retained for the 
analysis. These compounds were optimally aligned using atom-based flexible alignment 
method. To perform the atom-based 3D-QSAR, PHASE module of the Schrödinger 
program was used (46). This approach considers various properties of the molecule in 
space by constructing a potential grid around the aligned molecules. Each grid point in 
the 3D space is scored according to one or more of the following atomic properties: 
propensity for the site to be a H-bond donor, hydrophobic or nonpolar, negative or 
positive charge centers, electron withdrawing group (such as nonnitrogen and oxygen) 
and other atom-types. Using a grid spacing of 1 Å and partial least square (PLS) fitting 
model, QSAR model was generated. PLS factor of one was considered for the model 
generation and increasing the factor did not increase the predictive ability of the model. 
The model generated was visualized to understand the atomic properties and its role in 
predicting the binding activity. 
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COVALENT INHIBITION OF LYMPHOID TYROSINE  



















The balancing actions of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs) regulate tyrosine phosphorylation levels of cellular proteins which 
in turn regulate a multitude of cellular pathways (1). Aberrations in this highly regulated 
dynamic interplay lead to human diseases ranging from cancer to autoimmunity (2, 3). 
Therefore, both PTPs and PTKs have been recognized as relevant therapeutic targets for 
the treatment of these human disorders, but only PTK inhibitors have made it to the clinic 
thus far (4-6). This can be attributed to the fact that our understanding about actions, 
targets, regulation and biological roles of PTKs has surpassed that of PTPs (7). This is in 
part due to earlier notion that PTPs were simply ‘housekeeping’ enzymes that would 
dephosphorylate any target regardless of the surrounding amino acid sequence (3). 
However, it is now clear that PTPs exert exquisite substrate specificities as well as 
distinct physiological functions in vivo and inhibition of PTPs can be beneficial for 
therapeutic purposes (8, 9).  
The human genome contains 107 genes that are predicted to encode for PTPs or 
proteins with a domain homologous to the catalytic PTP domain and 81 of these genes 
encode for active PTPs (10). Although crucial roles played by several PTPs have been 
documented (11), there is still a dearth in knowledge about pathological and 
physiological roles of several other PTPs, their subcellular localization and mechanisms 
of regulations (12). While genomic techniques such as gene knockout, RNAi (RNA 
interference), real-time polymerase chain reaction (RT-PCR) and protein overexpression 
have contributed significantly to our understanding of PTPs to date, these approaches 
have limitations (13). These limitations are discussed in detail in Chapter 1. In short, gene 
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knockout is tedious and can lead to activation of compensatory mechanisms; RNAi 
suffers from insufficient delivery and nonspecific attenuation of translation; RT-PCR 
only determines the abundance of proteins and not the activities; and protein 
overexpression can lead to nonspecific activities of the protein (14). Chemical 
knockdown of proteins compliments genomic approaches by exerting their effects on the 
endogenous molecular targets under the physiological and pathological conditions to 
reveal key insights into the activities of the target proteins (15). In addition, the chemical 
probes used for the chemical knockdown can provide a direct validation of novel 
therapeutic targets and offer insights that can help in subsequent development of new 
therapeutic agents. 
As discussed in earlier chapters, lymphoid tyrosine phosphatase (LYP or 
PTPN22) has been recognized as an intriguing therapeutic target due to its association 
with human autoimmunity (16-19). Recently, our collaborators have used a selective 
LYP inhibitor developed by the Barrios Laboratory, C28, to create chemical knockdown 
of LYP in mast cells (20). Complimentary use of C28-mediated chemical knockdown of 
LYP and gene knockout was instrumental in establishing the positive regulatory role of 
LYP in mast cell degranulation and anaphylaxis. Furthermore, chemical knockdown of 
PEST-domain enriched tyrosine phosphatase (PEP), the mouse ortholog of LYP, was 
shown to alleviate anaphylaxis in mice. It was also shown that inhibition of PEP is 
synergistic with dexamethasone in the treatment of anaphylaxis. More detailed 
information on this study can be found in Chapter 1, section 1.3.2. This study underlines 
the importance of chemical knockdowns in studying the physiological and pathological 
roles of PTPs. 
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Despite this significant finding, very little information is available about the 
substrates, abundance, localization and regulation of LYP in mast cells. As discussed in 
detail in Chapter 1, LYP is also a negative regulator of T-cell receptor signaling (17). 
However, details of regulation of LYP in TCR signaling are still missing especially those 
pertaining to the abundance and subcellular localization of active versus inactive LYP in 
the presence of, as well as in the absence of TCR stimulation. Selective chemical probes 
that can help in visualization of the target protein upon its chemical knockdown can help 
in addressing these questions. 
Activity-based probes (ABPs) can effectively profile functional states of enzymes 
in complex environments which in turn can lead to target identification and discovery of 
previously uncharacterized enzyme activity by creating chemical knockdowns of the 
proteins of interest (21-23). ABPs used for protein profiling are comprised of three main 
structural features: a reactive unit (also known as a warhead), a linker and a tag  (Figure 
4.1) (12). The warhead inhibits target proteins by covalent bond formation with the active 
site. The reactivity of the warhead can be tailored to selectively target a subset of proteins 
(24). Several enzymes contain nucleophiles such as cysteine, serine or lysine in their 
active site and therefore, the warheads for these enzymes are electrophiles that can form 
covalent bonds with these nucleophiles. A visualization tag enables detection and 
characterization of proteins labeled by the warhead while a linker connects the warhead 
and the tag. Apart from imparting flexibility and accessibility, the linker region can also 
















Figure 4.1. Structure and utility of ABPs. ABPs comprise of a reactive unit (warhead), a 
linker and a tag. Upon binding with the target proteins, ABPs label them covalently and 
the labeled proteins can then be visualized using the properties of the tag. This figure is 







Although C28 has been instrumental in establishing role of LYP in anaphylaxis, 
unfortunately it cannot be used as a warhead in ABPs for LYP. This is because C28 is a 
gold(I) phosphine compound and the phosphine ligand falls off upon binding with LYP. 
Therefore, selective covalent inhibitors of LYP are necessary for developing ABPs for 
LYP as well as other PTPs. 
All the PTPs have highly conserved active site and dephosphorylate their 
substrates through a common catalytic mechanism that uses a low pKa, highly 
nucleophilic cysteine residue (25, 26). Therefore, it is quite intuitive that the ABPs for 
PTPs will contain phosphotyrosine (pY) mimicking, cysteine-reactive electrophilic 
moiety that form covalent bond with catalytic cysteine residue. Several such covalent 
inhibitors of PTPs have recently been described (Figure 4.2) (27-30). Some of the earliest 
molecules used for this purpose contained 4-fluoromethylphenyl phosphate moiety (for 
example, compound 1, Figure 4.2) that upon dephosphorylation by PTP generated a 
highly electrophilic quinone methide, which in turn can be attacked by a nucleophile to 
form a covalent bond (29, 30). Unfortunately, the quinone methide intermediate readily 
diffuses from the active site and has the undesired effect of covalently labeling other 
proteins nonspecifically. Other previously used warheads for PTPs contained α-
bromobenzylphosphonates (compound 2), aryl vinyl sulfones (compound 3) and aryl 
vinyl sulfonates (compound 4) (27, 28). Although these probes showed good selectivity 
for PTPs over other cysteine dependent enzymes, they lacked selectivity among the PTPs. 
These probes therefore are useful for probing the global PTP proteome in a cell, but there 














Figure 4.2. Covalent PTP inhibitors reported in literature. 1. Quinone-methide generating 
inhibitors 2. α-bromobenzylphosphonates 3. phenyl vinyl sulfone 4. phenyl vinyl 
sulfonate 5. 2-FMPT 6. 2-FMPCAP 7. Mal AA 
 
It is well known that although PTPs have highly conserved active site, PTPs 
exhibit high specificities towards their substrates through interactions of amino acid 
residues flanking pY of the substrate with the nonconserved features on the PTP surface 
(8). PTPs also show higher catalytic efficiency towards turning over peptide sequences 
containing pY than pY alone (31). Also various pY-containing peptides show a range of 
kcat/Km values and both N- and C-terminal residues contribute to the substrate recognition 
of PTPs. These results indicate that residues flanking pY in a PTP substrate contribute 







































hypothesized that an ABP approach that combines the selectivity of using peptide-based 
inhibitors with the utility of an electrophilic pY mimic would be a potentially effective 
tool for selectively exploring activities of individual PTPs and subfamilies of PTPs (12, 
32).  
Progress has been made in this direction, with the development of several amino 
acid derived covalent inhibitors that can, in principle, be incorporated into optimized 
peptide sequences and used to specifically target one member of the family (32-36). The 
amino acids incorporating quinone-methide generating moieties such as 2-
fluoromethylphosphotyrosine (2-FMPT, compound 5) (34, 35) and 2-fluoromethyl-
phosphocoumaryl aminopropionic acid (2-FMPCAP, compound 6) (33),   show improved 
selectivity when incorporated into peptide chain but still suffer from the inherent 
diffusibility of the quinone methides. L-bromophosphonomethylphenylalanine (BrPmp) 
(36) is quite challenging to synthesize in high purity and large quantities needed for 
peptide synthesis, compromising its feasibility as a widespread chemical probe. We have 
previously synthesized 4-maleimidophenyalanine (Mal AA, compound 7) in high 
quantities for incorporation into peptides but owing to the inherent high reactivity of the 
maleimido group, the peptide incorporating Mal AA do not achieve desired selectivity 
(32). Therefore, significant work still needs to be done in this area to develop selective, 
easy to synthesize, peptide-based covalent inhibitors of PTPs. 
 
4.2 Results and discussion 
With the aim of developing a general approach that can be ‘fine tuned’ to target 
individual PTPs selectively, we designed peptide-based cysteine-reactive covalent 
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inhibitors. These inhibitor probes take advantage of the selectivity offered by the peptide 
sequence and the utility offered by the electrophilic warhead. By changing the peptide 
sequence that offers selectivity, these inhibitors can be tailored to target different PTPs. 
In order to narrow down the best peptide-based covalent inhibitor for LYP, we decided to 
optimize peptide sequence and the electrophilic warhead separately and then combine the 
best peptide sequence and the best warhead to obtain our desired probe. For optimizing 
the electrophilic warhead, we initially decided to synthesize several modified amino acids 
appended with cysteine reactive electrophilic groups that can be incorporated in peptide 
chains. However, syntheses of these modified amino acids in high purity and yields was 
quite challenging, with major difficulties arising from purification. Therefore, in order to 
simplify the syntheses and purification of the peptide-based covalent inhibitors, we 

























As per this strategy, for optimization of the warhead, we decided to first 
synthesize a generic peptide sequence that is appended with a handle for performing click 
chemistry. In Chapters 1 and 2, I have discussed in detail that ARLIEDNE-pY-TAREG-
NH2 is an accurate mimic of Lck pY394, a biological substrate of LYP (37). Therefore by 
replacing pY of the biological substrate with the propargylglycine (Pra) residue, we 
obtained Ac-ARLIEDNE-(Pra)-TAREG-NH2. We also synthesized several aryl azides 
appended with electrophilic warheads (Figure 4.4) separately and clicked them onto Ac-
ARLIEDNE-(Pra)-TAREG-NH2 using copper catalyzed azide alkyne Huisgen 
cycloaddition to get the peptide-based covalent inhibitors of LYP.  
First, commercially available 4-azidophenacyl bromide (compound 8), an α-
halomethyl ketone, was clicked on Ac-ARLIEDNE-(Pra)-TAREG-NH2 to get Ac-
ARLIEDNE-(PhAcBr)-TAREG-NH2 (PhAcBr14mer) in a 45% yield. Other proposed 
aryl azides (Figure 4.4) are not commercially available and therefore we had to 







Figure 4.4. Aryl azide bearing pendant electrophiles for warhead optimization. 8. α-
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For the synthesis of aryl azides bearing acrylamide electrophile (compound 9), we 
first installed the electrophilic warhead onto 4-nitroaniline (Scheme 4.1). 4-
Nitrophenylacrylamide (12) was generated by coupling acryloyl chloride with 4-
nitroaniline using DIPEA as a base and DCM as solvent. The nitro group of the 4-
nitrophenylacrylamide was then reduced chemoselectively to corresponding amine (13) 
using stannous chloride. 4-Aminophenylacrylamide (13) was then converted to 4-
azidophenylacrylamide (9) by diazotization followed by substitution reaction using 
sodium azide. Compound 9 was then clicked onto Ac-ARLIEDNE-(Pra)-TAREG-NH2 to 
get Ac-ARLIEDNE-(Acr)-TAREG-NH2 (Acr14mer). 
4-Azidophenyl vinylsulfonamide (10) was synthesized by reacting 4-azidoaniline 
hydrochloride with 2-chloroethanesulfonyl chloride in DCM using triethylamine (TEA) 
as a base (Scheme 4.2). Apart from coupling, triethylamine also helps in 
dehydrohalogenation of 2-chloroethanesulfonyl moiety to give the vinylsulfonyl moiety 
in one step. The resulting vinylsulfonamide was obtained in quantitative yield and was  





































Scheme 4.2. Synthesis of 4-azidophenylvinylsulfonamide. 
 
Synthesis of 4-azidophenylvinylsulfonate (11) was carried out in 3 steps (Scheme 
4.3) starting with coupling of 4-N-Boc-aminophenol with 2-chloroethanesulfonyl 
chloride using sodium hydride as a strong base to obtain the vinylsulfonate (14). N-Boc 
group was then cleaved off and the resultant free amine (15) was replaced with azide by 
diazotization followed by substitution using sodium azide. The resulting compound 11 
was clicked onto Ac-ARLIEDNE-(Pra)-TAREG-NH2 to get Ac-ARLIEDNE-(VsO)-
TAREG-NH2 (VsO14mer). 
In order to establish that the clicked peptide-based covalent inhibitors have 
advantage over the small molecule warheads appended onto the peptides and just these 
flanking peptide sequence lacking the pY-binding pocket reactive moiety, we decided to 
study their LYP inhibition. VsO14mer (IC50 = 90 ± 8 µM) inhibited LYP much more 
potently than the corresponding small molecule, phenyl vinyl sulfonate (PhVsO, 
compound 4, IC50 = 350 ± 10 µM) that has previously been used as ABP for PTPs  
(Figure 4.5A) (28). This result is consistent with previous observation that peptide 
sequences help in potent binding of the substrates to PTPs (31). For studying whether just 



















Scheme 4.3. Synthesis of 4-azidophenylvinylsulfonate 
 
peptide based on the biological substrate of LYP but lacking a pY-binding pocket- (active 
site-) directed motif: Ac-ARLIEDNE-A-TAREG-NH2 (Ala14mer) and a peptide-
possessing the aryl ring to fit in active site but lack phosphate: Ac-ARLIEDNE-Y-
TAREG-NH2 (Tyr14mer). Tyr14mer is also the product of biological reaction of PTP. 
We found that while Tyr14mer (IC50 = 500 ± 25 µM) showed some inhibition of LYP at 
high concentrations, Ala14mer did not show much inhibition of LYP even at 1 mM 
concentration (Figure 4.5B). This indicates that the peptide sequence with some 
interactions with active site can help in potent inhibition of Lyp. However, higher 
inhibition potency can be derived through peptide sequenced that also contained a pY 
mimic (for example VsO14mer).   
Next, LYP inhibitory potencies of the clicked peptide appended with different 
electrophilic warheads were compared to determine the optimum warhead for potent LYP 
targeting (Figure 4.6). Clicked peptide with a pendant vinyl sulfonamide warhead 
(VsN14mer, IC50 = 60 ± 3 µM) was found to be the most potent LYP inhibitor closely 
followed by VsO14mer (IC50 = 90 ± 8 µM). PhAcBr14mer (IC50 = 200 ± 15 µM) and 















































Fig. 4.5. Clicked peptides inhibit LYP more potently than the corresponding small 
molecule or the peptide sequence. (A) Comparison of LYP inhibition of phenyl vinyl 
sulfonate (PhVSO, compound 4) and the clicked peptide containing vinyl sulfonate 
warhead. (B) Comparison of LYP inhibition of clicked peptide containing vinyl sulfonate 
























































Fig. 4.6. Comparison of LYP inhibition of clicked peptides appended with different 
electrophilic warheads. 
 
VsN14mer and VsO14mer but these peptides inhibited LYP with more potency than the 
small molecule compound 4, Ala14mer and Tyr14mer. This confirmed that our clicked 
peptides are superior inhibitors than the small molecule warheads and the peptide 
sequence itself and also the potency of LYP inhibition varies with the electrophilic 
warhead. Vinylsulfonamide warhead, owing to the most potent inhibition of LYP by 
VsN14mer, was confirmed as the optimum warhead for LYP. 
For optimizing the peptide sequence for potent and selective targeting of LYP, Dr. 
Ryan Mathews in the Barrios Laboratory used one-bead-one-compound (OBOC) library 
approach to screen combinatorial peptide libraries to identify the best LYP substrate. 
Although this substrate activity screening exercise helped in identifying several excellent 
substrates of LYP, only a handful of these substrates showed good selectivity for LYP 


























substrate that showed the most selectivity over the other highly homologous PTPs 
including PTP-PEST with kcat/Km, about 5-times higher for LYP than PTP-PEST. 
Combining the peptide sequence that showed the most selectivity for LYP over other 
homologous PTPs with the electrophilic warhead that showed most potent LYP 
inhibition, we obtained Ac-LDLL-(VsN)-SDDD-NH2 (LDVsN). LDVsN (IC50 = 20 ± 1 
µM) was found to inhibit LYP 3-fold more potently than VsN14mer (IC50 = 60 ± 3 µM), 
indicating that optimizing the peptide sequence can help in achieving desired inhibitory 
potency (Figure 4.7). Finally, the selectivity of LDVsN for targeting LYP was 
investigated by comparing LDVsN mediated inhibition of the homologous PTPs (Figure 
4.8). LDVsN was found to inhibit LYP with high selectivity over PTP1B (IC50 > 50 µM) 
and TCPTP (IC50 > 50 µM), and with moderate selectivity over CD45 (IC50 = 48 ± 3 
µM). However, LDVsN showed only low preference for inhibition of LYP over highly 
homologous PTP-PEST (IC50 = 33 ± 1 µM). These selectivity results were comparable to 
those obtained from substrate activity screening approach. In the future, our best covalent 
inhibitor, LDVsN will be tested in cells with the aim of using it in addressing biological 













































 Although several ABPs for PTPs are available, none of them target one PTP 
selectively over others. Peptide-based covalent inhibitors take advantage of the selectivity 
offered by the peptide sequence and the utility offered by the electrophilic warhead. 
Clicking aryl azides on Pra-peptides can help in synthesizing a combinatorial peptide-
based covalent inhibitor library that can be fine-tuned to target different PTPs. Clicked 
peptides inhibit LYP more potently than the small molecule electrophile or the peptide 
sequence itself. Inhibition potencies of the clicked peptides vary with the electrophile and 
the peptide sequence used. Among the electrophilic warheads studied, vinylsulfonamide 


























separately optimized LYP selective sequence helped in designing LDVsN probe. LDVsN 
was found to inhibit LYP potently over VsN14mer and LDVsN inhibited LYP selectively 
over other homologous PTPs. LDLL-(VsN)-SDDD will be studied in cells in the future 
with the aim of using it in activity-based protein profiling. 
 
4.4 Experimental section 
All reagents were obtained from commercial sources and used without further 
purification. All NMR spectra were recorded on a Mercury 400 MHz spectrometer and 
were referenced to residual solvent peaks or TMS (δ 0.00 ppm). Column chromatography 
was performed on EMD silica gel (60-200 mesh) or EMD alumina (80-200 mesh). Thin 
layer chromatography was performed on EMD silica gel 60 F254 or aluminum oxide 60 
F254 precoated aluminum plates (0.2mm thickness). cDNA fragments encoding the 
catalytic domains of LYP (aa 2-309) and PTP-PEST (aa 2-323) were cloned between the 
BamH1 and the Xho1 sites of pET28a plasmid (Novagen) in frame with a cleavable N-
terminal 6xHis-tag. Recombinant proteins were purified from lysates of IPTG-induced 
Escherichia coli BL21 cells by affinity chromatography on Ni-nitrilotriacetic acid 
columns. 6xHisHePTP was eluted using 250 mM imidazole. Untagged LYP and PTP-
PEST were eluted by incubating columns with thrombin, followed by removal of 
thrombin from the protein preparation by a second chromatography step on benzamidine 
columns. The catalytic domains of human recombinant CD45, PTP1B and TCPTP were 
obtained from Enzo life sciences. All of the activity assays involving LYP, PTP-PEST 
and CD45 were performed at ambient temperature using a buffer containing 50 mM Bis-
Tris, pH 6.5, 100 mM NaCl, 2 mM EDTA, and 0.01% Brij 35. Activity assays involving 
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PTP1B and TCPTP were performed at ambient temperature using a buffer containing 50 
mM Tris, pH 7.2, 100 mM NaCl, 2 mM EDTA, and 0.01% Brij 35. Enzymes were pre-
incubated with 0.5 mM TCEP for 30 min before adding inhibitor. Enzyme activity was 
measured at room temperature (21-24˚C) in black 96-well plates. Fluorescence data were 
collected on a Molecular Devices Spectramax M5 multimode plate reader with excitation 
and emission at 360 and 455 nm, respectively. The increase in the fluorescence due to the 
hydrolysis of the substrates was measured every 60 s for 30 min. Fluorescence values in 
the linear range of the Michaelis-Menten kinetics curve were used for the data analysis. 
 
4.4.1 Synthesis of 4-nitrophenyl acrylamide (12)  
4-Nitroaniline (5 mmol) was taken in a RBF and dry DCM (25 mL) 
was added to it under N2 atmosphere. The resulting solution was cooled to 
0°C and then DIPEA (7.5 mmol) and acryloyl chloride (10 mmol) were 
added to it. The reaction was allowed to warm up to room temperature and stirred 
overnight at room temperature and monitored by TLC using EtOAc:hexanes (30:70) as 
mobile phase. Once the reaction was complete, it was quenched with methanol and water. 
Reaction mixture was extracted with DCM and washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. Crude product was then purified by column 
chromatography on silica gel using gradient of EtOAc in hexanes as mobile phase to get 
the pure product. (Yield 42%) 
1H NMR (400 MHz, DMSO-d6) δ (ppm) 10.75 (s, 1H), 8.22 (d, J = 8.8 Hz, 2H), 




5.84 (d, J = 1.6, 10.0 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 164.5, 145.9, 
143.1, 131.9, 129.3, 125.7, 119.8. 
 
4.4.2 Synthesis of 4-aminophenyl acrylamide (13) 
4-Nitrophenyl acrylamide (2 mmol) was taken in a RBF and EtOAc 
(50 mL) was added to it. To the resulting solution was added SnCl2.2H2O (8 
mmol). The reaction was stirred at room temperature overnight and was 
monitored by TLC using EtOAc:hexanes (50:50) as mobile phase. Since the reaction did 
not proceed significantly at room temperature, it was then refluxed at 78°C for 48 h. 
Once the reaction was complete, it was cooled down to room temperature and quenched 
by stirring with 2N NaOH (50 mL) for 30 min. Reaction mixture was then extracted with 
EtOAc and washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure. Crude product was then purified by crystallization using EtOAc and hexanes. 
(Yield 60%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.35 (d, J = 8.4 Hz, 2H), 6.64 (d, J = 8.4 Hz, 
2H), 6.38 (d, J = 16.8 Hz, 1H), 6.23 (dd, J = 10.0, 16.8 Hz, 1H), 5.69 (d, J = 9.6 Hz, 1H). 
 
4.4.3 Synthesis of 4-azidophenyl acrylamide (9)  
4-aminophenyl acrylamide (0.5 mmol) was taken in a RBF and 
dissolved in 2M HCl (5 mL) and 500 µL of methanol was added to it and 
the reaction was cooled to 0°C. Conc. HCl (5 drops) was added to the 
reaction and the solution was stirred at 0°C for 30 min away from light. To this reaction, 






taking care not to let the reaction warm up. The reaction mixture was further stirred at 
0°C for 30 min. Then a pre-chilled solution of sodium azide (2.5 mmol) in water (2 mL) 
was added, dropwise, to the reaction slowly enough not to let the reaction warm up. The 
reaction was further stirred at 0°C for 2 h and then overnight away from the light, 
allowing it to gradually warm up to room temperature. The reaction was monitored by 
TLC using EtOAc:hexanes (30:70) as mobile phase. Once the reaction was complete, the 
reaction mixture was diluted with DCM and washed with chilled brine, dried over 
Na2SO4 and concentrated under reduced pressure. Crude product was then dissolved in 
DCM and purified by filtering over alumina bed and washing the alumina bed well with 
DCM. Combined DCM washings were evaporated under reduced pressure to get the pure 
product. (Yield 35%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.60 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 
2H), 6.42-6.46 (m, 1H), 6.22-6.28 (dd, J = 10.0, 16.8 Hz, 1H), 5.78 (d, J = 10.0 Hz, 1H). 
 
4.4.4 Synthesis of 4-azidophenyl vinylsulfonamide (10)  
4-Azidoaniline hydrochloride (0.5 mmol) was taken in a RBF and dry 
DCM (10 mL) was added to it under N2 atmosphere. The reaction mixture 
was cooled in the ice bath. Triethylamine (2 mmol) was then added to the 
RBF while stirring followed by 2-chloroethane sulfonyl chloride (1 mmol). The reaction 
was kept away from light and stirred overnight allowing it to warm up to room 
temperature and monitored by TLC using EtOAc:hexanes (30:70) as mobile phase. Once 
the reaction was complete, the reaction mixture was diluted with DCM and washed with 






was then dissolved in DCM and purified by filtering over alumina bed and washing the 
alumina bed well with DCM. Combined DCM washings were evaporated under reduced 
pressure to get the pure product. (Yield 99%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.77 (dd, J = 2.0, 8.8 Hz, 2H), 7.04 (dd, J = 
10.4, 16.8 Hz, 1H), 6.99 (d, J = 8.4 Hz, 2H), 6.29 (d, J = 16.4 Hz, 2H), 6.16 (d, J = 9.6 
Hz, 2H).  
 
4.4.5 Synthesis of 4-N-Boc-aminophenyl vinylsulfonate (14)  
4-N-Boc-aminophenol (5 mmol) was taken in a RBF and dry DMF (50 
mL) was added to it under N2 atmosphere. The resulting solution was cooled to 
0°C and sodium hydride (60% suspension in mineral oil) (16 mmol) was then 
added slowly to the RBF and stirred for 15 min. Next, 2-chloroethane sulfonyl chloride 
(10 mmol) was added, dropwise, to the reaction mixture while stirring. The reaction was 
allowed to warm up to room temperature and stirred overnight at room temperature and 
monitored by TLC using EtOAc:hexanes (30:70) as mobile phase. Once the reaction was 
complete, the reaction was quenched with methanol and water. Reaction mixture was 
extracted with DCM and washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. Crude product was then purified by column chromatography on silica 
gel using gradient of EtOAc in hexanes as mobile phase to get the pure product. (Yield 
25%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 8.02 (s, 1H), 7.38 (d, J = 8.8 Hz, 2H), 7.15 






= 10.0 Hz, 1H), 1.51 (s, 9H); 13C NMR (100 MHz, CDCl3) δ (ppm) 152.8, 144.7, 137.8, 
132.1, 123.1, 119.6, 81.2, 77.6, 77.5, 77.3. 
 
4.4.6 Synthesis of 4-aminophenyl vinylsulfonate (15)  
4-N-Boc-aminophenyl vinylsulfonate (1 mmol) was dissolved in DCM 
(10 mL) and trifluoroacetic acid (TFA) (1 mL) was added to it while stirring. 
The reaction was stirred at room temperature for 3 h and monitored by TLC 
using EtOAc:hexanes (50:50) as mobile phase. Once the reaction was complete, the 
reaction was basified with aq. NaHCO3 to quench the acid. Reaction mixture was 
extracted with DCM and washed with aq. NaHCO3, brine, dried over Na2SO4 and 
concentrated under reduced pressure. Crude product was then purified by column 
chromatography on neutral alumina using gradient of methanol in DCM as mobile phase 
to get the pure product. (Yield 90%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.00 (d, J = 8.4 Hz, 2H), 6.60-6.66 (m, 3H), 
6.33 (d, J = 16.4 Hz, 1H), 6.13 (dd, J = 10.0 Hz, 1H). 
 
4.4.7 Synthesis of 4-azidophenyl vinylsulfonate (11)  
Diazotization followed by substitution by sodium azide was carried out using 4-
aminophenyl vinylsulfonate (0.5 mmol) as described earlier in the synthesis of 
4-azidophenyl acrylamide (9). (Yield 55%) 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.20 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 
2H), 6.66 (dd, J = 9.6, 16.4 Hz, 1H), 6.37 (dd, J = 4.4, 16.8 Hz, 1H), 6.19 (d, J = 6.0, 










4.4.8 General procedure for peptide synthesis  
Solid phase peptide synthesis was carried out using Aaptech Focus XC automated 
peptide synthesizer. Rink Amide AM resin (0.1 mmol) was added to the reaction vessel 
(RV) of the peptide synthesizer and each amino acid in the sequence (3 equiv each) along 
with HOBT (5 equiv) were dissolved in 3 mL DMF and were added to the respective 
assigned amino acid vessel on the peptide synthesizer. Rink Amide AM resin was 
allowed to swell in 5 mL DMF while mechanically mixing for 30 min. DMF was then 
drained and N-terminal 9-fluorenylmethoxycarbonyl (Fmoc) group of the resin was then 
cleaved off using 3 mL 2% w/v Diazabicyclo[5.4.0]undec7-ene (DBU) in DMF for 15 
min. Deprotection step was repeated by draining this solution and then adding another 3 
mL of 2% DBU and mixing for an additional 15 min.  The fully deprotected resin was 
then washed with DMF (3x3 mL).  The desired amino acid along with HOBT was then 
preactivated with DICI (5 equiv) for 10 min.  The mixture was then added to the rinsed 
resin in RV and mixed for 90 min.  After coupling, the solution was drained and rinsed 
with DMF (3x3 mL) and deprotected with 3 mL 2% DBU as before and the cycle was 
repeated until each amino acid from C-terminus to N-terminus was added. After the 
coupling of the final amino acid (G), the resin was transferred to a manual peptide 
synthesis vessel. The resin was then deprotected and N-terminus was acetylated using 
acetic acid (3 equiv), (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate) (HCTU) (5 equiv) and diisopropylethylamine (DIPEA) (10 equiv) 
in 1 mL of DMF.  The resin was then washed with DMF (3x1 mL) and DCM (3x1 mL) 
and dried under vacuum. The peptide was cleaved from the resin using a cleavage 
cocktail containing 95% TFA (v/v), 2.5% water (v/v), and 2.5% TIS (v/v) overnight.  The 
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peptide was then collected under vacuum and the resin was rinsed with 1 mL TFA and 10 
mL water.  The collected solution was diluted with approx 35 mL water and lyophilized.  
The peptide was then purified by HPLC and characterized by MALDI-TOF.  
 
4.4.9 Synthesis of Ac-ARLIEDNE-(Pra)-TAREG-NH2 
Yield 20%. MS (MALDI-TOF) Calculated exact mass: 1608.8, Observed: 1609.8 
(100%), 1591.8 (80%) (Corresponds to m-H2O+1).  
 
4.4.10 Synthesis of Ac-ARLIEDNE-A-TAREG-NH2 
Yield 10%. MS (MALDI-TOF) Calculated exact mass: 1584.8, Observed: 1585.8 
(100%) 
 
4.4.11 Synthesis of Ac-ARLIEDNE-Y-TAREG-NH2 
Yield 8%. MS (MALDI-TOF) Calculated exact mass: 1676.8, Observed: 1677.9 
(60%), 1659.9 (100%) 
 
4.4.12 Synthesis of Ac-LDLL-(Pra)-SDDD-NH2 
Yield 7%. MS (MALDI-TOF) Calculated exact mass: 1040.5, Observed: 1063.5 
(100%)(Corresponds to m+Na).  
 
4.4.13 General procedure for click chemistry 
Peptide containing propargylglycine (3.5 µmol) was taken in a RBF and dissolved 
in a mixture of acetonitrile:DMSO:water (8:2:1) and stirred. To this, 2,6-lutidine (7 
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µmol), sodium ascorbate (3.5 µmol) and aryl azide (7 µmol) were added while stirring. 
After this, CuI (1.75 µmol) was added to the reaction mixture and the air in the reaction 
vessel was displaced by N2. The reaction was stirred overnight under N2, away from 
light. Upon completion, the solvents were lyophilized and the residue was dissolved in a 
mixture of acetonitrile and water and purified by HPLC and characterized by MALDI-
TOF. 
 
4.4.14 Synthesis of Ac-ARLIEDNE-(PhAcBr)-TAREG-NH2  
Yield 45%. MS (MALDI-TOF) Calculated exact mass: 1847.8, Observed: 1768.9 
(100%, m+1-80), 1770.8 (60%, m+1-78) These peaks correspond to the cations formed 
after the loss of Br. In this case Br seems to be falling off during Maldi-TOF. 
 
4.4.15 Synthesis of Ac-ARLIEDNE-(Acr)-TAREG-NH2  
Yield 30%. MS (MALDI-TOF) Calculated exact mass: 1797.9, Observed: 1798.8 
(100%) 
 
4.4.16 Synthesis of Ac-ARLIEDNE-(VsN)-TAREG-NH2  
Yield 40%. MS (MALDI-TOF) Calculated exact mass: 1832.8, Observed: 1833.6 
(100%) 
 
4.4.17 Synthesis of Ac-ARLIEDNE-(VsO)-TAREG-NH2  
Yield 40%. MS (MALDI-TOF) Calculated exact mass: 1833.8, Observed: 1834.9 
(100%) 
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4.4.18 Synthesis of Ac-LDLL-(VsN)-SDDD-NH2  
Yield 30%. MS (MALDI-TOF) Calculated exact mass: 1264.5, Observed: 1287.8 
(100%) 
 
4.4.19 In vitro inhibition assay  
The final concentration of Lyp used for in vitro assays was 5 nm. The final 
concentration of the DiFMUP used was 1.5 µM. The total DMSO concentration in each 
reaction was held constant at 6% of the total reaction volume (100 µL). Stock solutions 
and serial dilutions of the compounds for determination of IC50 were made in DMSO. 
Inhibitor was incubated with the enzyme for 15 min before initiating the activity assay by 
adding the substrate. The percent relative activity for each compound was determined by 
factoring the measured fluorescence values for the compound treated wells over the 
control wells treated with DMSO only. The resulting plot of inhibitor concentration 
versus percent enzyme activity provided the IC50 values. 
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